Page last updated: 2024-08-23

cabergoline and Pituitary Neoplasms

cabergoline has been researched along with Pituitary Neoplasms in 422 studies

Research

Studies (422)

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (0.95)	18.7374
1990's	29 (6.87)	18.2507
2000's	142 (33.65)	29.6817
2010's	178 (42.18)	24.3611
2020's	69 (16.35)	2.80

Authors

Authors	Studies
Alikasifoglu, A; Celik, NB; Gonc, EN; Kandemir, N; Ozon, ZA	1
Chen, S; Dong, J; Gu, J; Jiang, X; Li, D; Wen, X; Zou, Y	1
Cai, X; Cong, Z; Ma, C; Tang, C; Yang, J; Yuan, F; Zhu, J	1
Arnesi, M; Auriemma, RS; Cappabianca, P; Cavallo, LM; Colao, A; de Angelis, C; Negri, M; Pirchio, R; Pivonello, C; Pivonello, R; Solari, D	1
Auriemma, RS; Colao, A; Negri, M; Patalano, R; Pirchio, R; Pivonello, C; Pivonello, R	1
Charmandari, E; Gavra, M; Paltoglou, G; Vasilakis, IA	1
Campana, C; Canevari, FR; Caputo, M; Castelletti, L; Ferone, D; Ferrero, A; Gaggero, G; Gatto, F; Lania, A; Lavezzi, E; Marzullo, P; Nista, F; Rossi, DC; Zona, G	1
Canturk, S; Dogansen, S; Hacisahinogullari, H; Yarman, S	1
Colao, A; De Martino, MC; Pivonello, C; Pivonello, R; Simeoli, C	1
Borhan, MK; Tan, FHS	1
Cohen, D; Eshkoli, T; Fraenkel, M; Goldbart, A; Gorshtein, A; Greenman, Y; Shimon, I; Tsvetov, G; Yoel, U; Zaid, D	1
Barranco-Trabi, J; Elegino-Steffens, DU; Hussain, A; Minns, RM; Yiu, AC	1
Boguszewski, CL; Botelho, MS; Franzini, ÍA; Nunes-Nogueira, VDS	1
Han, C; Lin, S; Lou, X; Wu, ZB	1
Inder, WJ; Jang, C	1
Akirov, A; Duskin-Bitan, H; Masri-Iraqi, H; Rudman, Y; Shimon, I	1
Hamidianjahromi, A; Tritos, NA	1
Leshchenko, OY	1
Berberoğlu, M; Bilici, E; Ceran, A; Kontbay, T; Özsu, E; Şıklar, Z; Uyanık, R	1
Akbari, H; Golgiri, F; Kabootari, M; Khajavi, A; Mosalamiaghili, S; Shirmohammadli, H	1
Alcázar, V; Araujo-Castro, M; Biagetti, B; Casteràs, A; Cordido, F; Díez, JJ; Gómez, CG; Guerrero-Pérez, F; Iglesias, P; Izquierdo, BG; Pascual-Corrales, E; Pavón, I; Rivero, N; Torres, VV; Villabona, C	1
Amarù, J; Dogan, F; Feelders, RA; Ferone, D; Gatto, F; Hofland, LJ; Neggers, SJCMM; van der Lelij, AJ; van Koetsveld, PM	1
Durcan, E; Kadioglu, P; Kavla, Y; Ozkaya, HM; Özogul, YY; Poyraz, BC; Sahin, S; Sayitoglu, M; Sudutan, T	1
Arastu, MI; Curiale, AM; Lipton, BA; Longo, S; Nanda, S; Tessier, S	1
Bruehlman, RD; McKittrick, C; Winters, S	1
Akirov, A; Ayalon-Dangur, I; Duskin-Bitan, H; Gorshtein, A; Robenshtok, E; Shimon, I; Tsvetov, G	1
Bueno, CBF; de Castro Moreira, AR; Glezer, A; Grande, IPP; Maciel, GAR; Monteiro, ALS; Padula, M; Trarbach, E	1
Huang, Q; Li, M; Tan, J; Zeng, Y; Zhou, W; Zou, Y	1
Hu, B; Li, J; Li, X; Rao, Q; Wang, H; Wu, N; Zhu, D; Zhu, Y; Zhu, Z	1
Aung, AT; Teo, AE; Tng, EL	1
Auriemma, RS; Colao, A; Garifalos, F; Pirchio, R; Pivonello, C; Pivonello, R	1
Cescato, VAS; Cunha-Neto, MBC; Glezer, A; Musolino, NRC; Pinheiro, FMM; Silva, GO; Stumpf, MAM	1
Miller, KK; Tritos, NA	1
Attanasio, R; Basile, M; Bozzao, A; Cappabianca, P; Caputo, M; Cozzi, R; Cruciani, F; De Menis, E; Doglietto, F; Esposito, F; Ferrante, E; Ferraù, F; Grimaldi, F; Iatì, G; Lania, AG; Laureti, S; Lello, S; Locatelli, D; Maffei, P; Mazzatenta, D; Minniti, G; Mitrova, Z; Paoletta, A; Papini, E; Peri, A; Persichetti, A; Poggi, M; Rudà, R; Ruini, C; Samperi, I; Saulle, R; Scoppola, A; Settanni, F; Silvani, A; Simona Auriemma, R; Tortora, F; Vecchi, S; Veronese, N	1
Kadoya, M; Kanzaki, A; Katayama, S; Koyama, H	1
Farrant, MT; Gunn, AJ; Milsom, SR; O'Sullivan, SM; Ogilvie, CM	1
Lin, S; Wu, ZB; Zhang, A; Zhang, X	1
Díez, JJ; Iglesias, P; Villabona, C	2
Jung, H; Kim, D; Kim, K; Ku, CR; Lee, EJ	1
Duskin-Bitan, H; Shimon, I	1
Arvigo, M; Bruzzone, E; Dogan, F; Feelders, RA; Ferone, D; Gatto, F; Hofland, L; Lamberts, S; van der Pas, R; van Koetsveld, P	1
Dekkers, OM; Fleseriu, M; Karavitaki, N	1
Barbe, K; D'Haens, J; Gläsker, S; Stadnik, T; Unuane, D; Van Velthoven, V; Vermeulen, E	1
Espinosa-Cárdenas, E; Mendoza-Zubieta, V; Mercado, M; Ramírez-Rentería, C; Sánchez-García, M; Sosa-Eroza, E	2
Kawazoe, Y; Kumon, M; Moriya, S; Tateyama, S	1
Ilie, MD; Raverot, G	1
Giraldi, EA; Ioachimescu, AG	1
Bandgar, T; Jaiswal, SK; Lila, AR; Patil, V; Ramteke-Jadhav, S; Sankhe, S; Sarathi, V; Sehemby, M; Shah, N; Shah, R	1
Ahn, SS; Kim, D; Kim, EH; Kim, K; Ku, CR; Lee, EJ; Moon, JH; Park, YW	1
Bestwick, JP; Bhattacharyya, S; Boomla, K; Drake, WM; Lloyd, G; Steeds, RP; Stiles, CE	1
Andereggen, L; Christ, E; Frey, J	1
Ajzensztejn, M; Arya, VB; Aylwin, SJB; Bodi, I; Buchanan, CR; Hampton, T; Hulse, T; Kalitsi, J; Kalogirou, N; Kapoor, RR; Thomas, N	1
Astafyeva, LI; Kadashev, BA; Kalinin, PL; Melnichenko, GA; Sharipov, OI; Shishkina, LV; Sidneva, JG	1
Albarel, F; Amodru, V; Brue, T; Castinetti, F; Cuny, T; Dufour, H; Graillon, T; Morange, I	1
Akın, Ş; Candemir, B	1
Barlier, A; Brue, T; Culler, MD; Cuny, T; Datta, R; Defilles, C; Dufour, H; Figarella-Branger, D; Graillon, T; Halem, HA; Landsman, T; Mougel, G; Saveanu, A; Zhang, S	1
Duskin-Bitan, H; Gorshtein, A; Manisterski, Y; Masri, H; Rudman, Y; Shimon, I	1
Aberer, F; Obermayer-Pietsch, B; Pandis, M; Pieber, TR; Pilz, S; Posawetz, AS; Theiler-Schwetz, V; Trummer, C	1
Biermasz, NR; Chanson, P; Jorgensen, JOL; Kuhn, E; Weinreich, AA	1
Ach, K; Ach, T; Ben Abdelkrim, A; Chaieb, M; Elfekih, H; Hasni, Y; Kacem, M; Khaldi, S; Maaroufi, A; Saad, G	1
Akirov, A; Duskin-Bitan, H; Manisterski, Y; Masri-Iraqi, H; Pertzov, B; Rudman, Y; Shimon, I	1
Deluche, E; Géraud, F; Salle, H; Salle, L	1
Barbot, M; Ceccato, F; Lizzul, L; Scaroni, C; Voltan, G	1
Cai, L; Li, Q; Lu, J; Su, Z; Wang, C; Wu, Z; Xu, J; Xu, Y	1
Bronstein, MD; Greenman, Y	1
Ades, M; Alaithan, M; Le, H; Schwartz, BC	1
Biagetti, B; Casteràs, A; Cordero Asanza, E; Giralt-Arnaiz, M; Hernandez, I; Martinez-Saez, E; Ng-Wong, YK; Sarria-Estrada, S; Simò, R	1
Bulwer, C; Conn, R; Ederies, A; Ferrau, F; Kapur, S; Korbonits, M; Shankar, A; Spoudeas, HA	1
Barkan, AL; Hollon, TC; Savastano, LE; Sullivan, SE	1
Cai, L; Guo, YH; Le, WD; Leng, ZG; Lin, SJ; Lou, MQ; Shang, HB; Tang, H; Wu, ZB; Wu, ZR; Xue, YJ; Zhang, X; Zhao, W; Zhao, WG	1
Seow, CJ; Young, WF	1
Araujo, B; Belo, S; Carvalho, D	1
Croxson, MS; Holdaway, I; Kunasegaran, S; Murphy, R	1
Cosio, C; Fracassi, F; Garatti, M; Grinwis, GCM; Kooistra, HS; Luccardini, L; Sartori, E	1
Jamor, J; Tayae, M	1
Casulari, LA; de Castro, LF; Luiz Mendonça, J; Magalhães Gonzaga, MF; Naves, LA; Oton de Lima, B	1
Cao, L; Guo, YH; Leng, ZG; Lin, SJ; Shang, HB; Wu, ZB; Wu, ZR; Zhang, X; Zhang, Y; Zhao, WG	1
Caixàs, A; Caparrós, L; Giménez-Palop, O; Labad, J; Llorens, M; Montalvo, I; Palao, DJ; Pamias, M; Torralbas, J	1
Demidowich, AP; Hannah-Shmouni, F; Lodish, M; Rowell, J; Stratakis, CA	1
Chia, YY; Goh, GH; Mohan, N; Teo, K; Ting, E; Yeo, TT	1
Bilbao, I; Egaña, N; García, C; Olaizola, I	1
Brau, R; de Lourdes Miranda, M; Gutierrez, M; Hernán Martínez, J; Laboy-Ortiz, IE; Mangual, M; Mansilla, P; Palermo, C; Rivera, C; Sanchez, A; Trinidad, R; Velez-Maymí, S	1
Akinduro, OO; Akinduro, OT; Gupta, V; Olomu, O; Reimer, R	1
Berger, M; Cobb, MIH; Codd, P; Crowson, M; Husain, AM; Jang, D; Mintz-Cole, R	1
Bettendorf, M; Breil, T; Choukair, D; Inta, I; Jesser, J; Klose, D; Lorz, C; Mittnacht, J; Schulze, E	1
Deb, KS; Gupta, P; Kumar, N; Singh, J; Tundup, T; Verma, R	1
Bowling, MS; Jaffery, F; Zamudio, A	1
Gutierrez-Hartmann, A; Jirawatnotai, S; Kiyokawa, H; Kuzyk, C; Roof, AK; Trudeau, T; Wierman, ME	1
Arreola, R; Espinosa, E; Mendoza, V; Mercado, M; Ramírez-Rentería, C; Sosa-Eroza, E	1
Arambewela, M; Arshad, MF; Debono, M	1
Chin, M; Ishibashi, R; Kurosaki, Y; Maki, Y; Uchino, K; Yamagata, S	1
Huang, HY; Hui, GZ; Tang, H; Wu, ZB; Zhai, W	1
Cai, L; Cao, L; Guo, YH; Huang, JY; Liu, YT; Rui, WW; Shang, HB; Su, B; Tang, H; Wang, Y; Wei, YX; Wu, ZB; Wu, ZR; Yan, L; Yang, G; Yao, H; Zhang, XB; Zhang, Y; Zhao, WG	1
Maiter, D	1
Bettencourt-Silva, R; Carvalho, D; Pereira, J; Queirós, J	1
Batista, RL; Cescato, VAS; Cunha-Neto, MB; da Silva, GO; Herkenhoff, CGB; Medeiros, RSS; Musolino, NRC; Trarbach, EB	1
Bergsneider, M; Heaney, AP; Sergey, M; Wang, MB; Way, JS; Yong, WH; Zhang, D; Zhang, X	1
Abe, T; Ebashi, R; Koguchi, M; Masuoka, J; Nakahara, Y; Ogata, A; Shimokawa, S	1
Bolanowski, M; Hubalewska-Dydejczyk, A; Kos-Kudła, B; Lewiński, A; Ruchała, M; Zgliczyński, W	1
Agely, A; Chaichana, KL; Gupta, V; Middlebrooks, EH; Okromelidze, L; Vilanilam, GK	1
Albiger, N; Ceccato, F; Lombardi, G; Mazzai, L; Pambuku, A; Rolma, G; Scaroni, C; Zagonel, V	1
Cong, Z; Luo, X; Ma, C; Sun, R; Tang, C; Wen, G; Yang, J; Zhong, C; Zhu, J	1
Arosio, M; Ferrante, E; Giavoli, C; Indirli, R; Mantovani, G; Sala, E	1
Akinduro, OO; Bernet, V; Chaichana, KL; De Biase, G; Donaldson, A; Izzo, A; Lu, VM; Meyer, FB; Olomu, O; Quinones-Hinojosa, A; Van Gompel, JJ; Vilanilam, G	1
Abad López, A; Aller Pardo, J; Araujo-Castro, M; Kanaan Kanaan, L; Palacios García, N	1
Casulari, LA; de Castro, LF; de Fátima Magalhães Gonzaga, M; Kessler, IM; Mendonça, JL	1
Bolanowski, M; Colao, A; Kerlan, V; Komorowski, J; Kos-Kudła, B; Minuto, FM; Scaroni, C; Tabarin, A; Zgliczyński, W	1
Asha, HS; Cherian, KE; Paul, TV; Rajan, R	1
Brichta, CM; Krebs, A; Schwab, KO; van der Werf-Grohmann, N; Wurm, M	1
Ikeda, H; Tominaga, T; Watanabe, K; Yoshimoto, T	1
Amato, MC; Ciresi, A; Giordano, C; Guarnotta, V; Lo Castro, F	1
Rettinger, G; Rotter, N; Scheithauer, M; v Bomhard, A	1
Gadelha, MR; Moraes, AB; Silva, CM; Vieira Neto, L	1
Benbassat, C; Shimon, I	1
Anastasiou, A; Christoforidis, A; Dimitriadou, M; Pavlaki, A; Tsakalides, C	1
Auriemma, RS; Colao, A; Ferreri, L; Gasperi, M; Grasso, LF; Iacuaniello, D; Perone, Y; Pivonello, R; Simeoli, C	1
Gürbüz, BB; Gürbüz, F; Kör, Y; Küpeli, S; Yağcı-Küpeli, B; Yüksel, B; Zorludemir, S	1
Arnez, L; Biagetti, B; Dalama, B; Mesa, J; Obiols, G; Valladares, S	1
Beckers, A; Daly, A; Vroonen, L	1
Góth, M	1
Chng, E; Dalan, R	1
Abreu, A; Albarrán, AA; Carrasco, CA; Espinosa de los Monteros, AL; Gadelha, M; Mercado, M	1
Chang, TJ; Huang, TS; Kao, YH	1
Hwang, JH; Hwang, SK; Kim, S; Park, KS; Park, SH	1
Jensen, TS; Jørgensen, JO; Kallestrup, MM; Kasch, H; Nielsen, E; Østerby, T	1
Auriemma, RS; Colao, A; Galdiero, M; Gasperi, M; Giordano, C; Granieri, L; Mannarino, T; Negri, M; Perone, Y; Pivonello, C; Pivonello, R; Simeoli, C; Vitale, P	1
Bakoto, N; Baleriaux, D; Boscolo, M; Corvilain, B; Devuyst, F	1
Fuentes Uliaque, C; Fustero de Miguel, D; Moles Herbera, J; Montejo Gañan, I; Rivero Celada, D; Vela Marín, AC	1
Barkan, A; Benbassat, C; Bronstein, MD; Shapiro, J; Shimon, I; Tsvetov, G	1
Figueroa-Núñez, C; González, E; Gutierrez, M; Hernán Martínez, J; Mangual-García, M; Mansilla-Letelier, P; Miranda, Mde L; Palermo-Garofalo, C; Sánchez, A; Santiago, M; Torres, O; Trinidad, R	1
Bonadei, I; Curnis, A; D'Aloia, A; Metra, M; Piovanelli, B; Rovetta, R; Vizzardi, E	1
Bronstein, MD; Glezer, A	1
Câmara, VL; Costa, EM; Cunha, FS; Domenice, S; Gooren, LJ; Mendonça, BB; Sircili, MH	1
Alhowsawi, G; Aljohani, N; Almalki, MH; Alshahrani, F; Alsherbeni, S; Alzahrani, S; Buhary, B	1
Bogazzi, F; Cosottini, M; Lombardi, M; Lupi, I; Manetti, L; Martino, E; Raffaelli, V; Rossi, G; Sardella, C	1
Cleemann, L; Holm, K; Jarløv, AE; Lewis, A	1
Fujii, S; Kambe, A; Kurosaki, M; Ogawa, T; Watanabe, T	1
Colli, LM; de Castro, M; Gadelha, MR; Gasparetto, EL; Kasuki, L; Marques, NV; Moraes, AB; Takiya, CM; Vieira Neto, L; Wildemberg, LE	1
Caputo, C; Inder, WJ; Prior, D	1
Hu, J; Yang, H; Zhang, W; Zheng, X	1
Auriemma, RS; Cariati, F; Colao, A; Coppola, G; de Angelis, C; Ferreri, L; Galdiero, M; Granieri, L; Lo Calzo, F; Pivonello, C; Pivonello, R; Salzano, C; Vitale, P	1
Cámara Gómez, R; Del Olmo García, M; Merino Torres, JF; Querol Ripoll, R; Simal Julián, JA	1
Auriemma, RS; Colao, A; Ferreri, L; Pivonello, R; Priscitelli, P	1
Evran, S; Hanimoglu, H; Ilhan, MM; Kaynar, MY; Tasan, E; Turgut, S	1
Baumgarten, E; Connemann, B; Feneberg, E; Gahr, M; Merger, S; Özpeynirci, Y; Schönfeldt-Lecuona, C	1
Couldwell, WT; Eloy, JA; Liu, JK; Wong, A	1
Benbassat, C; Shimon, I; Tirosh, A	1
Galofré, JC; Pascual-Corrales, E; Salvador, J; Tomás Velázquez, A; Zubieta, JL	1
Ilhan, M; Kahraman, OT; Karaman, O; Shukurov, S; Tasan, E; Turan, S; Turgut, S; Yaylim, I; Zeybek, U	1
Couldwell, WT; Eloy, JA; Hajart, AF; Jethwa, PR; Liu, JK; Patel, TD	1
Chatterjee, S; Das, A; Maiti, A	1
Ahuja, A; Bhardwaj, M; Dutta, D; Kulshreshtha, B; Sharma, L	1
Arduç, A; Berker, D; Doğan, BA; Güler, S; Işık, S; Nasıroğlu, NI; Tuna, MM	1
Dogansen, SC; Selcukbiricik, OS; Tanrikulu, S; Yarman, S	1
Auriemma, RS; Colao, A; Grasso, LF; Pivonello, R	1
Başer, H; Çakır, B; Ersoy, R; Kaya, C; Tam, AA	1
Alfieri, A; Ballarino, MC; Boero, L; Chervin, A; Danilowicz, K; Diez, S; Fainstein Day, P; García-Basavilbaso, N; Glerean, M; Guitelman, M; Katz, D; Loto, MG; Mallea-Gil, MS; Manavela, M; Martinez, M; Miragaya, K; Moncet, D; Rogozinski, AS; Servidio, M; Stalldecker, G; Vitale, M	1
D'Sylva, C; Fraser, LA; Khan, T; Van Uum, S	1
De Pue, A; Lutin, B; Paemeleire, K	1
Okazaki, K; Sugimoto, T; Takeno, A; Yamaguchi, T; Yamamoto, M	1
Ishikura, R; Koyama, H; Kurajoh, M; Moriwaki, Y; Namba, M; Okazaki, H; Shiraishi, J; Shirakawa, M; Shoji, T; Yamamoto, T	1
Bronstein, MD; Espinosa, E; Glezer, A; Greenman, Y; Mendoza, V; Mercado, M; Popovic, V; Shimon, I; Sosa, E; Tirosh, A	1
Cooper, O; Gertych, A; Greenman, Y; Jonas-Kimchi, T; Melmed, S; Ram, Z; Robenshtok, E; Sagiv, N; Shimon, I; Stern, N; Yaish, I; Yuan, X	1
Bellaviti Buttoni, P; Carosi, G; Ferrante, E; Filopanti, M; Malchiodi, E; Mantovani, G; Profka, E; Rodari, G; Sala, E; Spada, A; Verrua, E	1
Gemmete, JJ; Hollon, TC; Khalsa, SS; Pandey, AS; Shastri, R; Trobe, JD	1
Andrysiak-Mamos, E; Kaźmierczyk-Puchalska, A; Kojder, I; Sagan, L; Sowińska-Przepiera, E; Syrenicz, A; Zochowska, E	1
Damiani, D; de F Presti, P; Faria, AM; Musolino, NR; Neto, MB	1
Berriel, MR; Lima, GA; Melo, AS; Rahhal, H; Santos, ML; Taboada, GF	1
Altamura, AC; Cremaschi, L; Fiorentini, A; Lindenmayer, JP; Mauri, MC; Rovera, C; Serati, M; Thanju, A	1
Corn, HJ; Couldwell, WT; Eli, IM; Palmer, CA; Raheja, A; Simmons, DL	1
Librizzi, R; Obermayer-Pietsch, B; Pieber, TR; Pilz, S; Schwetz, V; Stiegler, C; Theiler, G; Trummer, C	1
Hide, T; Honda, Y; Kuratsu, JI; Mikami, Y; Uekawa, K; Yano, S	1
Chapman, IM; De Sousa, SM; Falhammar, H; Torpy, DJ	1
Brue, T; Castinetti, F; Cebula, H; Goichot, B; Graillon, T; Képénékian, L	1
Atkinson, JL; Donegan, D; Erickson, B; Erickson, D; Jentoft, M; Meyer, F; Natt, N; Nippoldt, TB	1
Andereggen, L; Andres, RH; Beck, J; Christ, E; El-Koussy, M; Frey, J; Seiler, RW	1
Auriemma, R; Beckers, A; Daly, AF; Dulgheru, R; Garcia, MT; Lancellotti, P; Magne, J; Maiga, I; Petrossians, P; Rubio-Almanza, M; Vroonen, L	1
Akturk, HK; Nippoldt, TB	1
Beshyah, SA; Chentli, F; El-Fikki, M; Hamrahian, A; Jambart, S; Khalil, AB; Raef, H; Sherif, IH	1
Arslan, MS; Cakal, E; Caliskan, M; Demirci, T; Karakose, M; Ozbek, M; Ozdemir, S; Sahin, M; Topaloglu, O; Tutal, E; Ucan, B	1
Bhadada, SK; Bhansali, A; Rastogi, A	1
Dhanjal, MK; Knight, M; Lambert, K; McCance, DR; Rees, K; Seed, PT; Williamson, C	1
Chanson, P; Kuhn, E	1
Beckers, A; Bonneville, JF; Brue, T; Castinetti, F; Cuny, T; Dufour, H; Eroukhmanoff, J; Potorac, I; Tejedor, I; Touraine, P; Weryha, G	1
Barbieri, F; Culler, MD; Dong, J; Dufour, H; Feelders, RA; Florio, T; Gunz, G; Hofland, LJ; Jaquet, P; Moreau, JP; Saveanu, A; Spaziante, R; Stalla, GK; Taylor, JE; Theodoropoulou, M; van Koetsveld, PM; Zona, G	1
Bax, JJ; Delgado, V; Feelders, RA; Holman, ER; Kars, M; Pereira, AM; Romijn, JA; Smit, JW	1
Borson-Chazot, F; Delemer, B; Jacob, M; Jouanneau, E; Pugeat, M; Raverot, G; Vighetto, A	1
Colao, A; D'Andrea, M; Di Sarno, A; Gaccione, M; Galderisi, M; Guerra, E; Lerro, G; Lombardi, G; Pardo, M; Pivonello, R	1
Arda, N; Comlekci, A; Men, S; Yener, S; Yesil, S	1
Bax, JJ; Kars, M; Pereira, AM; Romijn, JA	1
Pobereskin, L; Vaidya, B; Watt, A	1
Banerjee, A; Hatfield, EC; Martin, NM; Meeran, K; Tan, T; Williamson, C; Wynne, K	1
Amano, K; Hori, T; Kawamata, T; Kubo, O; Makino, R; Miki, N; Ono, M; Seki, T; Takano, K	1
Jin, ZM	1
Buchfelder, M	1
Molitch, ME	6
Angelini, F; Barini, A; Bianchi, A; de Marinis, L; Fusco, A; Lauriola, L; Lugli, F; Maira, G; Pontecorvi, A; Sacco, E; Tilaro, L; Tofani, A	1
Ballarino, C; Becu-Villalobos, D; Cristina, C; Mallea-Gil, MS; Perez-Millan, MI; Stalldecker, G; Villafañe, AM	1
Agha, A; Behan, LA; Crowley, RK; Draman, MS; King, T; Moran, C; O'Sullivan, EP; Smith, D; Thompson, CJ	1
Abs, R; Daems, T; Delgrange, E; Maiter, D; Verhelst, J	1
Falhammar, H; Yarker, JY	1
Courtney, HC; Hunter, SJ; Johnston, PC; Mc Cance, DR	1
Kharlip, J; Salvatori, R; Wand, GS; Yenokyan, G	1
Albuquerque, LA; Almeida, JP; Ferraz, CL; Ferraz, TM; Gondim, J; Mota, I	1
Dhanwal, DK; Sharma, AK	1
Bridgman, P; Cawood, TJ; Cole, D; Hunter, L	1
Ryan, FJ; Spinks, JJ	1
Biller, BM; Grinspoon, S; Klibanski, A; Lawson, EA; Lo, J; McCarty, D; Miller, KK; Nachtigall, LB; Passeri, J; Utz, A; Valassi, E	1
Matsuno, A	1
Bahuleyan, B; Easwer, HV; Krishna, K; Menon, G; Nair, S; Rao, BR	1
Cho, EH; Cho, YH; Chung, JY; Kim, CJ; Kim, JH; Kim, MS; Koh, EH; Lee, SA	1
Schteingart, DE	1
Colao, A; Loche, S	1
Cervantes, CE; Da Costa, CV; Hernando, CA; Vargas, ML	1
Ambrosio, MR; Buratto, M; Degli Uberti, EC; Filieri, C; Lapparelli, M; Minoia, M; Scanarini, M; Tagliati, F; Zatelli, MC	1
Serri, K; Serri, O; Vallette, S	1
Amano, K; Hori, T; Izumi, S; Kawamata, T; Makino, R; Miki, N; Okada, Y; Ono, M; Seki, T; Takano, K	1
Klibanski, A	1
Bernard, P; Hubinont, C; Lebbe, M; Maiter, D	1
Balcik, O; Buyukbayrak, EE; Karageyim Karsidag, AY; Kars, B; Pirimoglu, M; Turan, C; Unal, O	1
Balzaretti, M; Carrizo, A; Christiansen, S; Fainstein Day, P; Glerean, M; Kozak, A; Lovazzano, S; Pietrani, M	1
Gittoes, NJ; Harries, AM; Mitchell, RD	1
Benjamin, J; Chawda, S; Nkonge, FM; Sharif, DA; Stojanović, ND	1
Burger, P; Menucci, M; Quiñones-Hinojosa, A; Salvatori, R	1
Bianchi, A; Carrozza, C; D'Ercole, M; Della Pepa, GM; Doglietto, F	1
Beuls, EA; Cornips, EM; Kubben, PL; Looij, BJ	1
Carroll, PV; Chambers, J; Gu, H; Luck, S; Powrie, J	1
Harrisson, SE; Mathad, NV; Zaben, MJ	1
Díez, JJ; Iglesias, P	2
Astaf'eva, LI; Kadashev, BA; Kalinin, PL; Kutin, MA	1
Connemann, BJ; Gahr, M; Schönfeldt-Lecuona, CJ	1
Barbieri, F; Culler, MD; Ferone, D; Florio, T; Gatti, M; Gatto, F; Giusti, M; Hofland, LJ; Minuto, F; Ravetti, JL; Saveanu, A; Schulz, S; Wurth, R; Zona, G	1
DeCubellis, J; Donnelly, T; Kiupel, M; Mayer, J; Sato, A	1
Bhadada, S; Bhansali, A; Dutta, P; Khandelwal, N; Sialy, R; Walia, R	1
Akutsu, H; Matsumura, A; Sato, H; Takano, S; Watanabe, S	1
Annamalai, AK; Antoun, NM; Dash, S; Mannion, R; Sarkies, N; Simpson, HL	1
Castro-Castro, J; Pastor-Zapata, A; Pinzón-Millán, A; Torre-Eiriz, JA	1
Cottier, JP; François, P; Gilbert-Dussardier, B; Girard, JJ; Jan, M; Lecomte, P; Richard, S; Trouillas, J; Tudorancea, A	1
Chatziioannou, S; Filippopoulou, A; Lykouras, L; Peppa, M; Rizos, E; Tsigkaropoulou, E; Xelioti, I; Zompola, C	1
Barlier, A; Couderc, B; Cuny, T; Defilles, C; Enjalbert, A; Figarella-Branger, D; Germanetti, AL; Graillon, T; Mohamed, A; Roche, C; Saveanu, A	1
Ambrosio, MR; Buratto, M; degli Uberti, E; Filieri, C; Frank, G; Gagliano, T; Lapparelli, M; Minoia, M; Tagliati, F; Zatelli, MC; Zoli, M	1
Malkani, S; Mehta, NK; Ockene, I	1
Maiter, D; Primeau, V	1
Elenkova, A; Kalinov, K; Shabani, R; Zacharieva, S	1
Bilge, A; Kurtulmus, N; Yarman, S	1
Bussone, G; Moschiano, F; Usai, S	1
Athanasoulia, AP; Brockhaus, AC; Ising, M; Sievers, C; Stalla, GK; Uhr, M; Yassouridis, A	1
Anholm, C; Baltzar, MT; Petersen, CD	1
Azevedo, MF; Casulari, LA; de Castro, LF; Garcia, EC; Naves, LA; Silva, AO	1
Ahmed, A; Furqan, S; Islam, N	1
Machicado, JD; Orlander, PR; Varghese, JM	1
Beck-Peccoz, P; Beckers, A; Borson-Chazot, F; Brue, T; Caron, P; Chanson, P; Ciccarelli, E; Daly, AF; Delemer, B; Gatta, B; Jaffrain-Rea, ML; Naves, LA; Petrossians, P; Tamagno, G; Vilar, L; Vroonen, L	1
Deukmedjian, AR; Hann, S; Morrison, AD; Shah, V; Vale, FL	1
Barahona Constanzo, MJ; del Pozo Picó, C	1
Shahzad, H; Sheikh, A; Sheikh, L	1
Auriemma, RS; Colao, A; Di Sarno, A; Gasperi, M; Grasso, LF; Guerra, E; Perone, Y; Pivonello, R	1
Alkabbani, A; Doshi, K; Hamrahian, A; Hatipoglu, B; Kennedy, L; Makin, V; Mon, SY; Olansky, L; Thorton, JN; Weil, R	1
Byrne, JV; Dobrescu, R; Grossman, AB; Karavitaki, N; Wass, JA	1
Bilal, L; Ching, C	1
Bath, L; Cackett, P; Eunson, G; Mulvihill, A	1
Cakir, B; Caner, S; Ersoy, R; Inancli, SS; Tam, AA; Usluogullari, A; Ustu, Y	1
Anand, KS; Dhikav, V	1
Bianchi, A; De Marinis, L; Doglietto, F; Giampietro, A; Iacovazzo, D; Lauriola, L; Lucci-Cordisco, E; Lugli, F; Milardi, D	1
Abaci, A; Altincik, A; Bober, E; Buyukgebiz, A; Can, S; Catli, G; Demir, K	1
Bhadada, SK; Bhansali, A; Dutta, P; Gupta, V; Rastogi, A; Sachdeva, N; Singh, P; Vijaivergiya, R; Walia, R	1
Biesold, M; Guenzel, S; Lohmann, T; Paschke, R; Prothmann, S; Schober, R; Trantakis, C	1
Liu, C; Tyrrell, JB	1
Freed, DJ; Gillam, MP; Middler, S; Molitch, ME	1
Keogh, MA; Wittert, GA	1
Akintoye, SO; Bianco, P; Booher, S; Chebli, C; Cherman, N; Collins, MT; Feuillan, P; Kushner, H; Leroith, D; Robey, PG; Wientroub, S	1
Cavallero, D; Fazzuoli, L; Giusti, M; Valenti, S	1
Goadsby, PJ; Levy, MJ; Matharu, MS	1
Biondi, B; Briganti, F; Cappabianca, P; Colao, A; Faggiano, A; Lombardi, G; Pivonello, R; Sarno, AD; Somma, CD	1
Bauduceau, B; Bordier, L; Dupuy, O; Le Marec, E; Mayaudon, H; Rilminger, H	1
Buchfelder, M; Harms, E; Hüfner, M; Saeger, W; Siggelkow, H	1
Altomare, M; Colosimo, C; Corsello, SM; Lovicu, RM; Migneco, MG; Rota, CA; Ubertini, G	1
Ball, SG; Hall, K; James, RA; Kendall-Taylor, P; Pearce, SH; Quinton, R; Sibal, L; Ugwu, P	1
Brabant, G; Bremer, M; Cuarezma, JS; Karstens, JH; Lenarz, T; Samii, M; Schöfl, C; Schöfl-Siegert, B; von zur Mühlen, A	1
Cappabianca, P; Colao, A; Di Sarno, A; Di Somma, C; Lombardi, G; Pivonello, R	1
Braucks, GR; Gadelha, MR; Naliato, EC; Tabet, AL; Violante, AH	1
Bolko, P; Jaskuła, M; Sowiński, J; Waśko, R; Wołuń, M	1
Friedman, TC	1
Couldwell, WT; Laws, ER; Weiss, MH	1
Ayala, AR; Hurtado Amador, R	1
Falaschi, P; Martocchia, A; Missale, C; Sigala, S; Spano, P	1
Annunziato, L; Cappabianca, P; Cavallo, LM; Colao, A; Di Somma, C; Filippella, M; Lombardi, G; Matrone, C; Pivonello, R	1
Briganti, F; Cappabianca, P; Ciccarelli, A; Colao, A; De Rosa, M; Lombardi, G; Vitale, G; Zarrilli, S	1
Chang, JY; Kattah, JC; Orth, EH; Talkad, AV; Xu, MY	1
Annunziato, L; Arvigo, M; Colao, A; De Caro, ML; de Herder, WW; Ferone, D; Hofland, LJ; Kros, JM; Lamberts, SW; Lombardi, G; Pivonello, R	1
Díez, JJ; Iglesias, P; Macho, LP	1
Ciccarelli, A; Colao, A; Di Sarno, A; Guerra, E; Lombardi, G; Spiezia, S; Vitale, G	1
Couldwell, WT; Liu, JK	1
Hermus, AR; Nooijen, P; Pieters, GF; van Alfen, N; van Lindert, E; van Uum, SH; Wesseling, P	1
Werner, S	1
Trifonov, I	1
Casulari, LA; Mello, PA; Naves, LA; Papadia, C; Pereira Neto, A	1
Freda, PU; Khandji, AG; Nuruzzaman, AT; Post, KD; Reyes, CM; Sundeen, RE	1
Date, I; Hashimoto, K; Inagaki, K; Makino, H; Miyoshi, T; Ogura, T; Otsuka, F; Suzuki, J; Takeda, M	1
Gomes, MC; Knoepfelmacher, M; Melo, ME; Mendonca, BB	1
Rickels, MR; Snyder, PJ	1
Abs, R; Verhelst, J	1
Goadsby, PJ; Levy, MJ; Matharu, MS; Meeran, K; Powell, M	1
Kawai, M; Misumi, S; Morimatsu, M; Negoro, K; Ogasawara, J; Tada, Y	1
Howell, DL; Hudgins, RJ; Mazewski, CM; Meacham, LR; Wasilewski, K	1
Biswas, M; Davies, JS; Evans, LM; Jadon, D; McEwan, P; Rees, DA; Scanlon, MF; Smith, J	1
Ball, SG; Connolly, V; James, RA; Kane, P; Kelly, WF; Kendall-Taylor, P; Mathias, D; Perros, P; Quinton, R; Sibal, L; Vaidya, B	1
Albertelli, M; Arvigo, M; Barreca, A; Culler, MD; Ferone, D; Jaquet, P; Minuto, F; Moreau, JP; Saveanu, A; Semino, C; Taylor, JE	1
Afandi, B; Al-Zubaidi, AS	1
Giovanelli, M; Losa, M; Mortini, P; Scarone, P	1
Crosignani, PG	1
Góth, MI; Iván, G; Nagy, GM; Oláh, M; Szigeti-Csúcs, N	1
Boianov, M; Khristov, V; Vezenkova, L	1
Bronstein, MD	2
Ciccarelli, A; Colao, A; De Rosa, M; Guerra, E; Lombardi, G; Milone, F; Zarrilli, S	1
Boulos, PT; Hamilton, DK; Laws, ER; Vance, ML	1
Elder, DA; Eyal, O; Naffaa, LN	1
Ciccarelli, A; Colao, A; De Rosa, M; Di Sarno, A; Gaccione, M; Guerra, E; Lombardi, G; Zarrilli, S	1
Delgrange, E; Duprez, T; Maiter, D	1
Fleseriu, M; Hamrahian, AH; Lee, M; Pineyro, MM; Reddy, SK; Siraj, ES; Skugor, M	1
Danilovic, DL; Knoepfelmacher, M; Mendonça, BB; Rosa Nasser, RH	1
Culler, MD; Dufour, H; Guillen, S; Gunz, G; Jaquet, P; Saveanu, A	1
de Herder, WW; Feelders, RA; Krenning, EP; Kwekkeboom, DJ; Reijs, AE; Tanghe, HL; van Aken, MO; van der Lely, AJ	1
Grotas, AB; Nagler, HM	1
Atkinson, AB; Cooke, RS; Herron, B; Hunter, SJ; McCall, D; Sheridan, B	1
Georgieva, J; Nussbaum, G; Rochlitz, H; Steinhoff, M; Zouboulis, CC	1
Christ, ER; Jenni, S; Seiler, R; Stettler, C	1
Jiménez Caballero, PE	1
Enseñat, J; Mesa, J; Obiols, G; Ortega, A; Sahuquillo, J; Topcewski, T; Vilalta, J	1
Grotenhuis, JA; Hermus, AR; Netea-Maier, RT; Schakenraad, EL; Timmers, H; van Lindert, EJ	1
Benbassat, C; Hadani, M; Shimon, I	1
Mascarell, S; Sarne, DH	1
Bianchi, F; Culler, MD; Dadati, P; Ferone, D; Jaquet, P; Minuto, F; Ravetti, JL; Rebora, A; Resmini, E; Saveanu, A; Spaziante, R; Zona, G	1
Bowsher, T; Chatfield, J; Loskutoff, N; O'Neill, K; Ramey, J; Zhang, L	1
Tokhunts, KA	1
Colao, A; Di Somma, C; Lombardi, G; Pivonello, R; Savastano, S; Tauchmanovà, L	1
Freeman, B; Gorman, JM; Levy, W	1
Atkin, SL; Lowry, M; Manuchehri, AM; Rowland-Hill, C; Sathyapalan, T; Turnbull, LW	1
Balarini Lima, GA; Dos Santos Silva, CM; Filho, PN; Gadelha, MR; Machado, Ede O	1
Briganti, F; Cappabianca, P; Caranci, F; Cavallo, LM; Cirillo, S; Colao, A; Di Sarno, A; Elefante, A; Guerra, E; Lombardi, G; Pivonello, R	1
Greenman, Y	1
Ciraru-Vigneron, N; Laloi-Michelin, M; Meas, T	1
Ali, O; Banerjee, S; Kelly, DF; Lee, PD	1
Besouw, MT; Levtchenko, EN; Noordam, K; Willemsen, MA	1
Adamo, V; Manno, M; Marchesan, E; Tomei, F	1
Allen, K; Byrne, JV; Cudlip, S; De Silva, SR; Soni, A; Wass, JA	1
De Tommasi, A; De Tommasi, C; Guastamacchia, E; Losa, M; Luzzi, S; Resta, F; Sabbà, C; Tafaro, E; Terreni, MR; Triggiani, V	1
Horikawa, F; Kawabata, Y; Miki, N; Miyake, H; Ono, M; Ueno, Y	1
Davie, M	1
Barlier, A; Brue, T; Jaquet, P; Saveanu, A	1
Caldas, D; Cesar de Oliveira Naliato, E; Colao, A; Dutra Violante, AH; Fontes, R; Gomes de Souza, R; Guerra, E; Lamounier Filho, A; Rezende Loureiro, C; Schrank, Y; Sebastian, A; Vaisman, M	1
Ambrosi, B; Angioni, AR; Baglioni, S; Barbieri, AM; Beck-Peccoz, P; Borretta, G; Brogioni, S; Cannavò, S; Colao, A; Filopanti, M; Fustini, MF; Gasco, V; Gasperi, M; Grottoli, S; Jaffrain-Rea, ML; Lania, A; Mantovani, G; Monte, PD; Peri, A; Pigliaru, F; Spada, A	1
Barlier, A; Culler, MD; Dufour, H; Fusco, A; Germanetti, AL; Gunz, G; Jaquet, P; Saveanu, A	1
Duarte, J; Fernández-Reyes, MJ; Heras, M; Iglesias, P; Jiménez, MJ; Muñoz, H; Sánchez, R; Tajada, P	1
Assaker, R; Blond, S; Cortet-Rudelli, C; Defoort-Dhellemmes, S; Faivre-Defrance, F; Mouton, F; Soto-Ares, G; Vantyghem, MC; Wemeau, JL	1
Arita, K; Eguchi, K; Ito, A; Kawamoto, K; Kurisu, K; Uozumi, T	2
Ajossa, S; Depau, GF; Guerriero, S; Mais, V; Melis, GB; Paoletti, AM	1
Delgrange, E; Donckier, J; Maiter, D	1
Biller, BM; Cannistraro, KB; Davis, KR; Klibanski, A; Molitch, ME; Schoenfelder, JR; Simons, JA; Vance, ML	1
Annunziato, L; Colao, A; Di Renzo, G; Di Sarno, A; Ferone, D; Lombardi, G; Merola, B; Sarnacchiaro, F	1
Abs, R; Bevan, JS; Brabant, G; Ciccarelli, E; Ferrari, CI; Motta, T; Mucci, M; Muratori, M; Musatti, L; Scanlon, MF; Verbessem, G	1
Delgrange, E; Donckier, J	1
Colao, A; Lombardi, G	1
Baylis, PH; Foster, S; Harris, PE; Hurel, SJ; Kelly, WF; McNicol, AM	1
Jeffreys, R; Leese, G; Vora, J	1
Annunziato, L; Cataldi, M; Cirillo, S; Colao, A; Di Sarno, A; Facciolli, G; Landi, ML; Lombardi, G; Merola, B; Pivonello, R; Sarnacchiaro, F	1
Arosio, M; Biella, O; Faglia, G; Gambino, G; Muratori, M; Romano, C	1
Bertagna, A; Camanni, F; Camanni, M; Cammarota, T; Ciccarelli, E; Cirillo, S; Gaia, D; Grottoli, S; Razzore, P	1
Abs, R; Beckers, A; Coolens, JL; Mahler, C; Maiter, D; Nobels, F; Van Acker, K; Verhelst, J	1
Crabbé, J; Delgrange, E; Donckier, J	1
Coppola, A; Cuomo, MA	1
Attanasio, R; Barausse, M; Branca, V; Cozzi, R; Da Re, N; Dallabonzana, D; Gelli, D; Oppizzi, G; Orlandi, P	1
Bartolone, L; Blandino, A; Cannavò, S; Galatioto, S; Spinella, S; Trimarchi, F	1
Almoto, B; Cannavò, S; Curtò, L; Squadrito, S; Trimarchi, F; Vieni, A	1
Abs, R; Beckers, A; Coremans, P; Lamberigts, G; Mahler, C; Maiter, D; Mockel, J; Petrossians, P; Raftopoulos, C; Stevenaert, A; van den Bruel, A; Vandeweghe, M; Velkeniers, B; Verhelst, J; Verlooy, J	1
Delgrange, E; Donckier, JE	1
Verhelst, JA	1
Kaltsas, T; Krassas, GE; Pontikides, N	1
Atkin, SL; Foy, PM; Hadden, DR; Leong, KS; MacFarlane, IA; Swift, AC	1
Colao, A; Di Salle, F; Faggiano, A; Filippella, M; Lombardi, G; Pivonello, R	1
Colao, A; Di Sarno, A; Di Somma, C; Klain, M; Loche, S; Lombardi, G; Pietrosante, M; Pivonello, R; Salvatore, M	1
Cerbone, G; Colao, A; Di Sarno, A; Di Somma, C; Ferone, D; Lastoria, S; Lombardi, G; Lucci, R	1
Dimitriadis, A; Galli-Tsinopoulou, A; Karamouzis, M; Mitsiakos, G; Nousia-Arvanitakis, S	1
Annunziato, L; Cappabianca, P; Cirillo, S; Colao, A; Di Salle, F; Di Sarno, A; Landi, ML; Lombardi, G; Pivonello, R; Scavuzzo, F; Volpe, R	1
Abs, R; Appel, B; Berwaerts, J; Mahler, C; Verhelst, J	1
Webster, J	2
Cerbone, G; Colao, A; Di Sarno, A; Di Somma, C; Landi, ML; Lombardi, G; Marzullo, P; Pivonello, R	1
Herman-Bonert, V; Kovacs, K; Maheshwari, HG; Melmed, S; Prezant, TR; Shahinian, H	1
Krassas, GE; Pontikides, N	1
Kaltsas, T; Krassas, GE; Nikopoulou, E; Pontikides, N	1
Davies, JS; George, LD; Nicolau, N; Scanlon, MF	1
Andersen, M; Bjerre, P; Edal, A; Hagen, C; Høilund-Carlsen, PF; Pedersen, PH; Schrøder, HD	1
Botella, I; De Luis, DA; Hurtado, A; Marcos, L	1
Beckers, A; Bloch, B; Kalife, A; Petrossians, P; Ronci, N; Stevenaert, A; Tabarin, A; Valdés Socin, H	1
Agostini, S; Billeci, D; Conte, N; De Menis, E; Marton, E; Tramontin, P; Visentin, A	1
Cappabianca, P; Cavallo, LM; Colao, A; Cozzi, R; Di Sarno, A; Felisati, G; Giombini, S; Lodrini, S; Peca, C	1
Cappabianca, P; Colao, A; Del Basso de Caro, ML; Faggiano, A; Ferone, D; Lastoria, S; Lombardi, G; Pivonello, R	1
Miki, N	1
Arikan, E; Hatemi, H; Sabuncu, T; Tasan, E	1
Cappabianca, P; Colao, A; Di Salle, F; Di Sarno, A; Di Somma, C; Faggiano, A; Landi, ML; Lombardi, G; Pivonello, R; Rossi, FW	1
Nippoldt, TB; Sheehan, MT	1
Cantore, G; Delfini, R; Esposito, V; Ferrante, L; Jaffrain-Rea, ML; Minniti, G; Santoro, A	1
Defeyter, I; Rubens, R; T'Sjoen, G; Van De Saffele, J; Vandeweghe, M	1
Colao, A; di Sarno, A; di Somma, C; Lombardi, G; Pivonello, R	1
Góth, M; Hubina, E; Kovács, L; Szabolcs, I	1
Crosignani, P; D'Alberton, A; de Vincentiis, S; Ferrari, C; Mattei, AM; Paracchi, A	1
Ambrosi, B; Conti, A; Faglia, G; Morabito, F; Muratori, M; Sartorio, A	1
Dominoni, P; Ferrari, L; Gianola, D; Gualteroni, L; Montini, M; Pagani, G; Pagani, MD; Sileo, F; Stroppa, S; Tengattini, F	1
Fioretti, P; Gambacciani, M; Mais, V; Melis, GB; Paoletti, AM; Sghedoni, D	1
Camanni, F; Ciccarelli, E; Giordano, G; Giusti, M; Miola, C; Potenzoni, F; Sghedoni, D	1
Crosignani, PG; Faglia, G; Ferrari, C; Mattei, A; Melis, GB; Muratori, M; Paracchi, A; Sghedoni, D	1
Cancio, E; Cocchi, D; Dall'Ara, A; Devesa, J; Di Salle, E; Lima, L; Müller, EE	1

Reviews

64 review(s) available for cabergoline and Pituitary Neoplasms

Article	Year
The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis. BMC endocrine disorders, 2021, Nov-13, Volume: 21, Issue:1 Topics: Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma	2021
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms. Frontiers in endocrinology, 2021, Volume: 12 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aminoquinolines; beta-Arrestins; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Filamins; Growth Hormone-Secreting Pituitary Adenoma; Humans; Lisuride; MicroRNAs; Pergolide; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2	2021
A rare case of a giant prolactinoma with atypical histological features: 5 years of follow-up. Hormones (Athens, Greece), 2022, Volume: 21, Issue:2 Topics: Adolescent; Cabergoline; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma	2022
Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature. Journal of endocrinological investigation, 2022, Volume: 45, Issue:8 Topics: Adenoma; Aged; Cabergoline; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pituitary Neoplasms; Prolactin; Retrospective Studies	2022
The dopaminergic control of Cushing's syndrome. Journal of endocrinological investigation, 2022, Volume: 45, Issue:7 Topics: Adrenal Gland Neoplasms; Cabergoline; Cushing Syndrome; Humans; Hydrocortisone; Pituitary ACTH Hypersecretion; Pituitary Diseases; Pituitary Neoplasms	2022
Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis. Pituitary, 2022, Volume: 25, Issue:6 Topics: Adenoma; Cabergoline; Humans; Pituitary Neoplasms	2022
Treatment of Prolactinoma. Medicina (Kaunas, Lithuania), 2022, Aug-13, Volume: 58, Issue:8 Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Female; Humans; Pituitary Neoplasms; Pregnancy; Prolactinoma; Treatment Outcome	2022
Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Reviews in endocrine & metabolic disorders, 2022, Volume: 23, Issue:5 Topics: Bromocriptine; Cabergoline; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms	2022
The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis. Frontiers in endocrinology, 2023, Volume: 14 Topics: Aminoquinolines; Bromocriptine; Cabergoline; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperprolactinemia; Pituitary Neoplasms	2023
Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature. Journal of medical case reports, 2023, Mar-17, Volume: 17, Issue:1 Topics: Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma	2023
Approach to the Patient With Prolactinoma. The Journal of clinical endocrinology and metabolism, 2023, 08-18, Volume: 108, Issue:9 Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hypogonadism; Male; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma	2023
How to manage intolerance to dopamine agonist in patients with prolactinoma. Pituitary, 2023, Volume: 26, Issue:2 Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma	2023
Diagnosis and Management of Pituitary Adenomas: A Review. JAMA, 2023, 04-25, Volume: 329, Issue:16 Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Child; Female; Human Growth Hormone; Humans; Hypopituitarism; Pituitary Neoplasms; Pregnancy; Prolactinoma	2023
Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications. Neuroendocrinology, 2020, Volume: 110, Issue:6 Topics: Antineoplastic Agents; Cabergoline; Dopamine Agonists; Humans; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Prolactinoma	2020
Prolactinomas in males: any differences? Pituitary, 2020, Volume: 23, Issue:1 Topics: Cabergoline; Dopamine Agonists; Humans; Hypogonadism; Male; Pituitary Neoplasms; Prolactinoma; Somatostatin; Temozolomide	2020
Efficacy of cabergoline and triptans for cluster-like headache caused by prolactin-secreting pituitary adenoma: A literature review and case report. Clinical neurology and neurosurgery, 2020, Volume: 196 Topics: Cabergoline; Headache; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Tryptamines	2020
Treatment Options for Gonadotroph Tumors: Current State and Perspectives. The Journal of clinical endocrinology and metabolism, 2020, 10-01, Volume: 105, Issue:10 Topics: Antineoplastic Agents; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Gonadotrophs; Humans; Immune Checkpoint Inhibitors; Pituitary Neoplasms; Radiopharmaceuticals; Somatostatin; Temozolomide; Treatment Outcome	2020
The Role of Dopamine Agonists in Pituitary Adenomas. Endocrinology and metabolism clinics of North America, 2020, Volume: 49, Issue:3 Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Human Growth Hormone; Humans; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2020
Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis. Clinical endocrinology, 2021, Volume: 94, Issue:3 Topics: Adolescent; Adult; Age Factors; Cabergoline; Dopamine Agonists; Female; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Young Adult	2021
The risks of medical treatment of prolactinoma. Annales d'endocrinologie, 2021, Volume: 82, Issue:1 Topics: Cabergoline; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Fibrosis; Heart Valve Diseases; Humans; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Substance-Related Disorders	2021
Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature. European journal of endocrinology, 2021, May-24, Volume: 185, Issue:1 Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Female; Humans; Pituitary Apoplexy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prolactinoma; Tumor Burden; Young Adult	2021
Clinical Features and Response to Treatment of Prolactinomas in Children and Adolescents: A Retrospective Single-Centre Analysis and Review of the Literature. Hormone research in paediatrics, 2018, Volume: 89, Issue:3 Topics: Adolescent; Antineoplastic Agents; Cabergoline; Child; Ergolines; Female; Germany; Humans; Male; Pituitary Neoplasms; Prolactinoma; Retrospective Studies	2018
Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology, 2019, Volume: 109, Issue:1 Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Humans; Pituitary Neoplasms; Prolactinoma	2019
Giant prolactinomas: the therapeutic approach. Clinical endocrinology, 2013, Volume: 79, Issue:4 Topics: Cabergoline; Combined Modality Therapy; Dopamine Agonists; Ergolines; Humans; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Treatment Outcome; Tumor Burden	2013
[Drug therapy for acromegaly]. Orvosi hetilap, 2013, Sep-29, Volume: 154, Issue:39 Topics: Acromegaly; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Interdisciplinary Communication; Membrane Proteins; Octreotide; Patient Care Team; Peptides, Cyclic; Pituitary Neoplasms; Somatostatin	2013
Pituitary apoplexy associated with cabergoline therapy. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2013, Volume: 20, Issue:12 Topics: Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Pituitary Apoplexy; Pituitary Neoplasms; Prolactinoma; Young Adult	2013
Acute aseptic meningitis as the initial presentation of a macroprolactinoma. BMC research notes, 2014, Jan-07, Volume: 7 Topics: Adult; Anti-Bacterial Agents; Blindness; Cabergoline; Combined Modality Therapy; Ergolines; Fever; Headache; Hormone Replacement Therapy; Humans; Hydrocortisone; Hypophysectomy; Hypopituitarism; Male; Meningitis, Aseptic; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactinoma; Sella Turcica; Third Ventricle; Thyroxine	2014
Prolactinomas, cabergoline, and pregnancy. Endocrine, 2014, Volume: 47, Issue:1 Topics: Animals; Antineoplastic Agents; Cabergoline; Ergolines; Female; Fetal Development; Humans; Hyperprolactinemia; Infertility, Female; Pituitary Neoplasms; Pregnancy; Prolactinoma	2014
The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:11 Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma	2015
Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary, 2015, Volume: 18, Issue:5 Topics: Biomarkers, Tumor; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Prolactinoma; Recurrence; Time Factors; Treatment Outcome; Tumor Burden	2015
Cabergoline use for pituitary tumors and valvular disorders. Endocrinology and metabolism clinics of North America, 2015, Volume: 44, Issue:1 Topics: Acromegaly; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Pituitary Neoplasms; Prolactinoma	2015
Update on prolactinomas. Part 2: Treatment and management strategies. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015, Volume: 22, Issue:10 Topics: Bromocriptine; Cabergoline; Disease Management; Dopamine Agonists; Drug Administration Schedule; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neuroendoscopy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Radiosurgery; Sphenoid Sinus	2015
The safety of treatments for prolactinomas. Expert opinion on drug safety, 2016, Volume: 15, Issue:4 Topics: Animals; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma; Safety	2016
Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis. Neuro endocrinology letters, 2015, Volume: 36, Issue:8 Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Hypogonadism; Male; Odds Ratio; Osteoporotic Fractures; Pituitary Neoplasms; Prevalence; Prolactinoma; Sex Factors; Spinal Fractures	2015
Cabergoline in acromegaly. Pituitary, 2017, Volume: 20, Issue:1 Topics: Acromegaly; Cabergoline; Dopamine Agonists; Ergolines; Human Growth Hormone; Humans; Pituitary Neoplasms; Receptors, Somatostatin	2017
Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. European journal of endocrinology, 2008, Volume: 159, Issue:4 Topics: Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Pituitary Neoplasms; Prolactinoma	2008
Management of aggressive pituitary adenomas: current treatment strategies. Pituitary, 2009, Volume: 12, Issue:3 Topics: Cabergoline; Dacarbazine; Dopamine Agonists; Ergolines; Female; Humans; Male; Pituitary Neoplasms; Somatostatin; Temozolomide	2009
Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary, 2011, Volume: 14, Issue:4 Topics: Antineoplastic Agents; Cabergoline; Drug Resistance, Neoplasm; Drug Tolerance; Ergolines; Female; Humans; Middle Aged; Pituitary Neoplasms; Prolactinoma	2011
[Recent trends in the pathophysiology and treatment of pituitary adenomas]. Brain and nerve = Shinkei kenkyu no shinpo, 2009, Volume: 61, Issue:8 Topics: Adenoma; Antineoplastic Agents; Cabergoline; Corticotropin-Releasing Hormone; Dacarbazine; Ergolines; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypothalamic Hormones; Incidental Findings; Neurosurgical Procedures; Octreotide; Pituitary Neoplasms; Prolactinoma; Receptors, Neuropeptide; Receptors, Pituitary Hormone-Regulating Hormone; Temozolomide	2009
Drugs in the medical treatment of Cushing's syndrome. Expert opinion on emerging drugs, 2009, Volume: 14, Issue:4 Topics: Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Antiparkinson Agents; Cabergoline; Cushing Syndrome; Ergolines; Human Growth Hormone; Humans; Hydrocortisone; Ketoconazole; Metyrapone; Pituitary Hormones; Pituitary Neoplasms	2009
Prolactinomas in children and adolescents. Endocrine development, 2010, Volume: 17 Topics: Adolescent; Antineoplastic Agents; Cabergoline; Child; Combined Modality Therapy; Ergolines; Growth; Growth Disorders; Humans; Pituitary Neoplasms; Prolactinoma	2010
[Cabergoline in hyperprolactinemia and valvular heart disease]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2009, Volume: 56, Issue:8 Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactin; Prolactinoma; Ultrasonography	2009
Clinical practice. Prolactinomas. The New England journal of medicine, 2010, Apr-01, Volume: 362, Issue:13 Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Visual Fields	2010
2012 update in the treatment of prolactinomas. Annales d'endocrinologie, 2012, Volume: 73, Issue:2 Topics: Cabergoline; Contraindications; Dopamine Agonists; Endocrinology; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma	2012
How to investigate and treat: headache and hyperprolactinemia. Current pain and headache reports, 2012, Volume: 16, Issue:4 Topics: Adult; Amenorrhea; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Tension-Type Headache; Tomography, X-Ray Computed; Treatment Outcome	2012
New prospects for drug treatment in Cushing disease. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2012, Volume: 59, Issue:10 Topics: Adenoma; Adrenocorticotropic Hormone; Animals; Cabergoline; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Ergolines; Etomidate; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Metyrapone; Mice; Mifepristone; Mitotane; Multicenter Studies as Topic; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; PPAR gamma; Pyridines; Rats; Somatostatin; Therapies, Investigational; Tretinoin	2012
[Optimization of the medical treatment for acromegaly]. Medicina clinica, 2013, Apr-20, Volume: 140, Issue:8 Topics: Acromegaly; Cabergoline; Combined Modality Therapy; Dopamine Agonists; Dosage Forms; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Randomized Controlled Trials as Topic; Receptors, Somatotropin; Somatostatin; Treatment Outcome	2013
Double pituitary adenomas. Endocrine, 2013, Volume: 43, Issue:2 Topics: Adenoma; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Comorbidity; Ergolines; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Neurosurgical Procedures; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Treatment Outcome	2013
Dopamine resistance of prolactinomas. Pituitary, 2003, Volume: 6, Issue:1 Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma	2003
Contemporary management of prolactinomas. Neurosurgical focus, 2004, Apr-15, Volume: 16, Issue:4 Topics: Bromocriptine; Cabergoline; Contraindications; Diagnosis, Differential; Ergolines; Female; Humans; Hypophysectomy; Magnetic Resonance Imaging; Male; Pituitary Diseases; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Radiosurgery; Remission Induction	2004
[Prolactinoma and pregnancy]. Akusherstvo i ginekologiia, 2004, Volume: 43 Suppl 2 Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma	2004
Hyperprolactinemia: pathophysiology and management. Treatments in endocrinology, 2003, Volume: 2, Issue:1 Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estrogens; Female; Humans; Hyperprolactinemia; Male; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma; Radiotherapy; Surgical Procedures, Operative	2003
Current treatment issues in female hyperprolactinaemia. European journal of obstetrics, gynecology, and reproductive biology, 2006, Apr-01, Volume: 125, Issue:2 Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Pregnancy; Prolactinoma	2006
Treatment of pituitary tumors: dopamine agonists. Endocrine, 2005, Volume: 28, Issue:1 Topics: Adenoma; Bromocriptine; Cabergoline; Dopamine; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Receptors, Dopamine	2005
Prolactinomas and pregnancy. Pituitary, 2005, Volume: 8, Issue:1 Topics: Aminoquinolines; Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma	2005
PRL secreting adenomas in male patients. Pituitary, 2005, Volume: 8, Issue:1 Topics: Age Factors; Cabergoline; Dopamine Agonists; Ergolines; Humans; Libido; Male; Pituitary Neoplasms; Prevalence; Prolactin; Prolactinoma; Prostatic Hyperplasia; Semen; Sex Factors; Spermatogenesis; Testis	2005
Pharmacologic resistance in prolactinoma patients. Pituitary, 2005, Volume: 8, Issue:1 Topics: Bromocriptine; Cabergoline; Cell Proliferation; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Resistance; Ergolines; Estrogens; Female; Humans; Male; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine D2	2005
Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Molecular and cellular endocrinology, 2008, May-14, Volume: 286, Issue:1-2 Topics: Adenoma; Antineoplastic Agents, Hormonal; Cabergoline; Cell Proliferation; Dopamine; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Octreotide; Pituitary Neoplasms; Protein Multimerization; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin; Tumor Cells, Cultured	2008
[Prolactinoma in the male. Physiopathological, clinical, and therapeutic features]. Minerva endocrinologica, 1998, Volume: 23, Issue:1 Topics: Cabergoline; Cranial Irradiation; Dopamine Agonists; Erectile Dysfunction; Ergolines; Galactorrhea; Gynecomastia; Humans; Hyperprolactinemia; Hypophysectomy; Infertility, Male; Libido; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	1998
CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clinical endocrinology, 2000, Volume: 52, Issue:1 Topics: Adult; Bromocriptine; Cabergoline; Cerebrospinal Fluid Rhinorrhea; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Tomography, X-Ray Computed	2000
A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature. Journal of endocrinological investigation, 2000, Volume: 23, Issue:6 Topics: Cabergoline; Dopamine Agonists; Ergolines; Exophthalmos; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma	2000
Clinical management of prolactinomas. Bailliere's best practice & research. Clinical endocrinology & metabolism, 1999, Volume: 13, Issue:3 Topics: Bone Density; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hypogonadism; Male; Pituitary Neoplasms; Pregnancy; Prolactinoma	1999
Dopamine receptor agonists for treating prolactinomas. Expert opinion on investigational drugs, 2002, Volume: 11, Issue:6 Topics: Aminoquinolines; Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Ergot Alkaloids; Female; Humans; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma	2002
[Novel pharmacologic therapies in acromegaly]. Orvosi hetilap, 2002, May-12, Volume: 143, Issue:19 Suppl Topics: Acromegaly; Adenoma; Aminoquinolines; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Hormones; Human Growth Hormone; Humans; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Prolactin; Receptors, Somatotropin; Somatostatin	2002

Trials

34 trial(s) available for cabergoline and Pituitary Neoplasms

Article	Year
Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR. Endocrine, 2018, Volume: 61, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Child; Delayed-Action Preparations; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Prolactinoma; Proof of Concept Study; Treatment Outcome; Young Adult	2018
Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial. American journal of clinical oncology, 2019, Volume: 42, Issue:2 Topics: Adenoma; Antiparkinson Agents; Cabergoline; Disease Management; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm, Residual; Pituitary Neoplasms; Prognosis; Receptors, Dopamine D2; Survival Rate	2019
Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study Endokrynologia Polska, 2019, Volume: 70, Issue:4 Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Cabergoline; Drug Therapy, Combination; Female; Human Growth Hormone; Humans; Longitudinal Studies; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Treatment Outcome	2019
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. European journal of endocrinology, 2013, Volume: 169, Issue:3 Topics: Adult; Antineoplastic Agents; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Monitoring; Early Diagnosis; Ergolines; Female; Follow-Up Studies; Heart Valve Diseases; Heart Valves; Humans; Italy; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Severity of Illness Index; Time Factors; Ultrasonography	2013
Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Resistance; Ergolines; Female; Humans; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Young Adult	2008
Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia. Archives of gynecology and obstetrics, 2010, Volume: 282, Issue:5 Topics: Adolescent; Adult; Cabergoline; Chi-Square Distribution; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Young Adult	2010
Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? Clinical endocrinology, 2011, Volume: 74, Issue:5 Topics: Adult; Antineoplastic Agents; Artifacts; Bias; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Pituitary Neoplasms; Prolactinoma; Tricuspid Valve Insufficiency	2011
Does hypopituitarism recover when macroprolactinomas are treated with cabergoline? Clinical endocrinology, 2013, Volume: 79, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hypopituitarism; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies	2013
Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine, 2013, Volume: 44, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Biomarkers; Cabergoline; Carotid Intima-Media Thickness; Ergolines; Female; Glucose Tolerance Test; Humans; Inflammation; Insulin Resistance; Middle Aged; Pituitary Neoplasms; Prolactinoma; Young Adult	2013
A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma. Clinical endocrinology, 2013, Volume: 79, Issue:3 Topics: Adult; Antineoplastic Agents; Cabergoline; Drug Administration Schedule; Echocardiography; Ergolines; Female; Humans; Luminescence; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Prospective Studies; ROC Curve; Treatment Outcome; Young Adult	2013
Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary, 2001, Volume: 4, Issue:3 Topics: Adenoma; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Treatment Outcome; Visual Acuity	2001
Circulating nitric oxide changes throughout the menstrual cycle in healthy women and women affected by pathological hyperprolactinemia on dopamine agonist therapy. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2002, Volume: 16, Issue:5 Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Humans; Hyperprolactinemia; Luteal Phase; Menstrual Cycle; Nitric Oxide; Ovulation; Pituitary Neoplasms; Progesterone; Prolactinoma; Reference Values	2002
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. European journal of endocrinology, 2003, Volume: 148, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Follow-Up Studies; Galactose; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Sex Characteristics; Sexual Dysfunction, Physiological; Treatment Outcome; Visual Fields; Weight Gain	2003
Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary, 2002, Volume: 5, Issue:4 Topics: Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Follicle Stimulating Hormone; Humans; Hypopituitarism; Luteinizing Hormone; Male; Middle Aged; Pergolide; Pituitary Function Tests; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone; Thyrotropin	2002
The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type. Polskie Archiwum Medycyny Wewnetrznej, 2003, Volume: 109, Issue:5 Topics: Adult; Cabergoline; Dopamine Agonists; Drug Tolerance; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2	2003
Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:4 Topics: Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Semen; Treatment Outcome	2004
Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:6 Topics: Adult; Cabergoline; Case-Control Studies; Dihydrotestosterone; Dopamine Agonists; Ergolines; Humans; Male; Middle Aged; Pilot Projects; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Prostate; Prostatic Hyperplasia; Testosterone; Ultrasonography	2004
[Suppression of hyperprolactinemia in pituitary microadenoma with cabergoline (Dostinex)]. Akusherstvo i ginekologiia, 2005, Volume: 44, Issue:5 Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Prolactin; Treatment Outcome; Tumor Burden	2005
Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology, 2006, Volume: 83, Issue:3-4 Topics: Adenoma; Adult; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine; Drug Screening Assays, Antitumor; Ergolines; Female; Human Growth Hormone; Humans; Ligands; Male; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; Recombinant Fusion Proteins; RNA, Messenger; Somatostatin; Tumor Cells, Cultured	2006
[Comparative evaluation of effectiveness of treatment of hyperprolactinemia]. Georgian medical news, 2007, Issue:142 Topics: Adenoma; Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Ovulation; Pituitary Neoplasms; Treatment Outcome	2007
Quality of life in women with microprolactinoma treated with dopamine agonists. Pituitary, 2008, Volume: 11, Issue:3 Topics: Adult; Antineoplastic Agents; Brazil; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Health Status Indicators; Humans; Hyperprolactinemia; Middle Aged; Multivariate Analysis; Pituitary Neoplasms; Prolactin; Prolactinoma; Quality of Life; Reproducibility of Results; Surveys and Questionnaires; Treatment Outcome	2008
Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. European journal of endocrinology, 1996, Volume: 134, Issue:4 Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Prolactinoma	1996
Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:11 Topics: Adolescent; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Time Factors; Treatment Outcome; Visual Field Tests	1997
Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. Journal of endocrinological investigation, 1997, Volume: 20, Issue:9 Topics: Acromegaly; Adenoma; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin-Like Growth Factor I; Middle Aged; Pituitary Neoplasms; Pregnancy; Prolactin	1997
Cabergoline in the treatment of acromegaly: a study in 64 patients. The Journal of clinical endocrinology and metabolism, 1998, Volume: 83, Issue:2 Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prospective Studies	1998
Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? European journal of endocrinology, 1998, Volume: 139, Issue:5 Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin	1998
Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. Journal of endocrinological investigation, 1999, Volume: 22, Issue:5 Topics: Adolescent; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactin; Prolactinoma; Treatment Outcome	1999
Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clinical endocrinology, 2000, Volume: 52, Issue:4 Topics: Adenoma; Adult; Aminoquinolines; Benzamides; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Middle Aged; Patient Selection; Pituitary Neoplasms; Predictive Value of Tests; Prolactin; Prolactinoma; Radionuclide Imaging	2000
Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. The Journal of clinical endocrinology and metabolism, 2000, Volume: 85, Issue:6 Topics: Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Treatment Outcome	2000
The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical endocrinology, 2000, Volume: 53, Issue:1 Topics: Adult; Aminoquinolines; Cabergoline; Cross-Over Studies; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine D2; Treatment Outcome	2000
Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas. Pituitary, 2000, Volume: 2, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents; Cabergoline; Child; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Time Factors; Visual Fields	2000
Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Internal medicine (Tokyo, Japan), 2001, Volume: 40, Issue:9 Topics: Adult; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Treatment Outcome	2001
Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:11 Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Radioimmunoassay; Retrospective Studies	2001
Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. The Journal of clinical endocrinology and metabolism, 1989, Volume: 68, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Cabergoline; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Placebos; Prolactin; Prolactinoma; Radiography	1989

Other Studies

324 other study(ies) available for cabergoline and Pituitary Neoplasms

Article	Year
Management of prolactinomas in children and adolescents; which factors define the response to treatment? Pituitary, 2022, Volume: 25, Issue:1 Topics: Adolescent; Cabergoline; Child; Dopamine Agonists; Female; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Young Adult	2022
ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways. Endocrine-related cancer, 2021, 12-13, Volume: 29, Issue:2 Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Cabergoline; Drug Resistance, Neoplasm; Drug Synergism; Early Growth Response Protein 1; Furans; Humans; Pituitary Neoplasms; Prolactinoma; TOR Serine-Threonine Kinases	2021
Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment. Frontiers in endocrinology, 2021, Volume: 12 Topics: Adult; Blood Glucose; Cabergoline; Combined Modality Therapy; Dopamine Agonists; Female; Humans; Insulin; Insulin Resistance; Male; Metabolome; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactinoma; Treatment Outcome; Young Adult	2021
Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas. Journal francais d'ophtalmologie, 2022, Volume: 45, Issue:5 Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Female; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Vision Disorders; Visual Fields	2022
Aggressive giant prolactinoma: a case report. Journal of medical case reports, 2022, Apr-30, Volume: 16, Issue:1 Topics: Adolescent; Adult; Cabergoline; Female; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Temozolomide; Young Adult	2022
Resistant prolactinomas: a case series of 26 patients. Endocrine, 2022, Volume: 77, Issue:2 Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Young Adult	2022
Ectopic Cavernous Sinus Microprolactinoma Treated Medically. Military medicine, 2023, 05-16, Volume: 188, Issue:5-6 Topics: Adult; Cabergoline; Cavernous Sinus; Dopamine; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma	2023
Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report. Frontiers in endocrinology, 2022, Volume: 13 Topics: Adult; Cabergoline; Ergolines; Humans; Hydroxychloroquine; Lactotrophs; Male; Neuroendocrine Tumors; Pituitary Neoplasms; Prolactin; Prolactinoma; Young Adult	2022
Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma. Pituitary, 2022, Volume: 25, Issue:6 Topics: Adult; Cabergoline; Humans; Hypogonadism; Hypopituitarism; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Testosterone	2022
[Hyperprolactinemia in the postmenopause: versions and contraversions]. Terapevticheskii arkhiv, 2021, Oct-15, Volume: 93, Issue:10 Topics: Cabergoline; Dopamine Agonists; Estrogens; Female; Humans; Hyperprolactinemia; Neoplasm Recurrence, Local; Pituitary Neoplasms; Postmenopause; Progestins; Prolactin; Prolactinoma	2021
Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience. The Turkish journal of pediatrics, 2022, Volume: 64, Issue:5 Topics: Adolescent; Cabergoline; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Infant; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies	2022
Metabolic effects of dopamine-agonists treatment among patients with prolactinomas. Endocrine, 2023, Volume: 79, Issue:3 Topics: Adult; Blood Glucose; Body Mass Index; Cabergoline; Cholesterol, HDL; Dopamine; Dopamine Agonists; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Risk Factors; Triglycerides	2023
Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma. Journal of neuro-oncology, 2022, Volume: 160, Issue:2 Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Humans; Male; Middle Aged; Pituitary Neoplasms; Retrospective Studies; Treatment Outcome	2022
Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors. The Journal of clinical endocrinology and metabolism, 2023, 04-13, Volume: 108, Issue:5 Topics: Acromegaly; Cabergoline; Human Growth Hormone; Humans; Octreotide; Pituitary Neoplasms; Prolactin; Receptors, Somatostatin; RNA, Messenger	2023
A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients With Prolactinoma. The Journal of clinical endocrinology and metabolism, 2023, 05-17, Volume: 108, Issue:6 Topics: Cabergoline; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Pituitary Neoplasms; Prolactinoma; Serotonin Plasma Membrane Transport Proteins	2023
Long-term low-dose cabergoline usage: Another association with cardiac valvulopathy. Echocardiography (Mount Kisco, N.Y.), 2023, Volume: 40, Issue:1 Topics: Bromocriptine; Cabergoline; Ergolines; Heart Valve Diseases; Humans; Middle Aged; Pituitary Neoplasms	2023
Galactorrhea: Rapid Evidence Review. American family physician, 2022, Volume: 106, Issue:6 Topics: Cabergoline; Female; Galactorrhea; Humans; Hyperprolactinemia; Pituitary Neoplasms; Pregnancy; Prolactin; Thyrotropin	2022
Natural history of nonfunctioning pituitary macroadenomas followed without intervention: A retrospective cohort study. Clinical endocrinology, 2023, Volume: 98, Issue:4 Topics: Adenoma; Aged; Aged, 80 and over; Cabergoline; Humans; Hypopituitarism; Male; Middle Aged; Pituitary Neoplasms; Retrospective Studies; Treatment Outcome	2023
PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance. The Journal of clinical endocrinology and metabolism, 2023, Jun-16, Volume: 108, Issue:7 Topics: Animals; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Humans; Male; Mice; Mice, Knockout; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Prolactin; Retrospective Studies	2023
CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma. Journal of endocrinological investigation, 2023, Volume: 46, Issue:8 Topics: Cabergoline; Dopamine Agonists; Ferroptosis; Humans; MicroRNAs; Pituitary Neoplasms; Prolactinoma	2023
Italian Guidelines for the Management of Prolactinomas. Endocrine, metabolic & immune disorders drug targets, 2023, Volume: 23, Issue:12 Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Prolactin; Prolactinoma	2023
Syndrome of inappropriate antidiuretic hormone with recurrent giant cabergoline-resistant prolactinoma. BMJ case reports, 2023, Sep-28, Volume: 16, Issue:9 Topics: Aged; Cabergoline; Humans; Inappropriate ADH Syndrome; Pituitary Neoplasms; Prolactin; Prolactinoma; Vasopressins	2023
An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists. The Australian & New Zealand journal of obstetrics & gynaecology, 2020, Volume: 60, Issue:3 Topics: Abortion, Spontaneous; Adenoma; Adolescent; Adult; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Female; Humans; Infertility; Lactation; Pituitary Neoplasms; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Retrospective Studies; Young Adult	2020
Effects of cabergoline therapy on serum IGF-1 concentrations in prolactinoma patients. Pituitary, 2020, Volume: 23, Issue:2 Topics: Cabergoline; Dopamine Agonists; Ergolines; Humans; Insulin-Like Growth Factor I; Pituitary Neoplasms; Prolactinoma	2020
Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy. European journal of endocrinology, 2020, Volume: 182, Issue:2 Topics: Adult; Cabergoline; Decision Making; Female; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies	2020
β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids. The Journal of endocrinology, 2020, Volume: 245, Issue:1 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Aged; Animals; Anti-Inflammatory Agents; beta-Arrestin 1; beta-Arrestin 2; Cabergoline; Cell Line, Tumor; Dexamethasone; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Ketoconazole; Male; Mice; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Gland; Pituitary Neoplasms	2020
Endocrinology in the time of COVID-19: Management of pituitary tumours. European journal of endocrinology, 2020, Volume: 183, Issue:1 Topics: Adenoma; Antineoplastic Agents, Hormonal; Cabergoline; Coronavirus Infections; COVID-19; Disease Management; Dopamine Agonists; Hormone Replacement Therapy; Human Growth Hormone; Humans; Neurosurgical Procedures; Octreotide; Pandemics; Peptides, Cyclic; Pituitary Apoplexy; Pituitary Neoplasms; Pneumonia, Viral; Practice Guidelines as Topic; Radiotherapy; Somatostatin; Telemedicine; Time Factors; Visual Field Tests	2020
Predictors of dopamine agonist resistance in prolactinoma patients. BMC endocrine disorders, 2020, May-19, Volume: 20, Issue:1 Topics: Adult; Aged; Belgium; Cabergoline; Dopamine Agonists; Drug Resistance; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Predictive Value of Tests; Prolactin; Prolactinoma; Retrospective Studies; Tertiary Care Centers; Young Adult	2020
High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment? Endocrine, 2020, Volume: 70, Issue:1 Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma	2020
Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline. The Journal of clinical endocrinology and metabolism, 2020, 12-01, Volume: 105, Issue:12 Topics: Adult; Cabergoline; Cross-Sectional Studies; Down-Regulation; Humans; Hypogonadism; Luteinizing Hormone; Male; Middle Aged; Pituitary Neoplasms; Prognosis; Prolactin; Prolactinoma; Prospective Studies; Remission Induction; Retrospective Studies; Signal Transduction; Testosterone; Treatment Outcome; Young Adult	2020
Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma. The Journal of clinical endocrinology and metabolism, 2021, 01-23, Volume: 106, Issue:2 Topics: Adolescent; Adult; Biomarkers, Pharmacological; Biomarkers, Tumor; Cabergoline; Cohort Studies; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm, Residual; Pituitary Neoplasms; Prolactinoma; Remission Induction; Republic of Korea; Retrospective Studies; Treatment Outcome; Withholding Treatment; Young Adult	2021
Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints. The Journal of clinical endocrinology and metabolism, 2021, 01-23, Volume: 106, Issue:2 Topics: Adult; Biomarkers; Cabergoline; Case-Control Studies; Cohort Studies; Echocardiography; Female; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Incidence; London; Male; Middle Aged; Pituitary Neoplasms; Primary Health Care; Prolactinoma	2021
Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated. Endocrine, 2021, Volume: 72, Issue:1 Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma	2021
[Changes in the morphological structure of giant prolactinoma during treatment with cabergoline]. Problemy endokrinologii, 2020, 09-16, Volume: 66, Issue:3 Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma	2020
Letter to "High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?" Endocrine, 2021, Volume: 71, Issue:1 Topics: Cabergoline; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma	2021
Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Pituitary, 2021, Volume: 24, Issue:3 Topics: Adenoma; Cabergoline; Dopamine; Human Growth Hormone; Humans; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin; Tumor Cells, Cultured	2021
Response to Letter to the Editor: "High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?" Endocrine, 2021, Volume: 71, Issue:1 Topics: Cabergoline; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma	2021
True hyperprolactinemia in men without visible pituitary adenoma. Endocrine, 2021, Volume: 72, Issue:3 Topics: Adenoma; Adult; Aged; Cabergoline; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Young Adult	2021
Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study. BMC endocrine disorders, 2021, Apr-26, Volume: 21, Issue:1 Topics: Adiposity; Adult; Austria; Body Composition; Body Mass Index; Cabergoline; Case-Control Studies; Dyslipidemias; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Lipid Metabolism; Male; Middle Aged; Overweight; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Young Adult	2021
Pituitary apoplexy of a giant prolactinoma during pregnancy. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2021, Volume: 37, Issue:9 Topics: Adult; Cabergoline; Cytoreduction Surgical Procedures; Fatal Outcome; Female; Humans; Infertility; Magnetic Resonance Imaging; Pituitary Apoplexy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy, Twin; Premature Birth; Prolactin; Prolactinoma	2021
Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter? Clinical endocrinology, 2021, Volume: 95, Issue:4 Topics: Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome	2021
A prolactinoma resistant to cabergoline: The important role of surgery. Revue neurologique, 2021, Volume: 177, Issue:9 Topics: Cabergoline; Dopamine Agonists; Humans; Pituitary Neoplasms; Prolactinoma	2021
Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients. Pituitary, 2021, Volume: 24, Issue:6 Topics: Anastrozole; Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma	2021
Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas. Oxidative medicine and cellular longevity, 2021, Volume: 2021 Topics: Adenoma; Animals; Cabergoline; Dopamine Agonists; Female; Humans; Mice; Mice, Nude; Pituitary Neoplasms; Quassins; Xenograft Model Antitumor Assays	2021
Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma. European journal of endocrinology, 2021, Aug-27, Volume: 185, Issue:4 Topics: Adenoma; Cabergoline; Chemotherapy, Adjuvant; Disease Progression; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Neurosurgical Procedures; Patient Selection; Pituitary Neoplasms; Practice Patterns, Physicians'; Tumor Burden	2021
A Cerebrospinal Case of Dyspnea. The American journal of medicine, 2021, Volume: 134, Issue:12 Topics: Cabergoline; Cerebrospinal Fluid Rhinorrhea; Dopamine Agonists; Dyspnea; Humans; Male; Middle Aged; Pituitary Neoplasms; Pneumonia; Prolactinoma	2021
Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. European journal of endocrinology, 2021, Sep-01, Volume: 185, Issue:4 Topics: Adolescent; Adult; Aged; Cabergoline; Child; Drug Resistance, Neoplasm; Female; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prognosis; Prolactinoma; Remission Induction; Retrospective Studies; Spain; Time Factors; Treatment Outcome; Tumor Burden; Young Adult	2021
Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. Clinical endocrinology, 2017, Volume: 86, Issue:6 Topics: Adolescent; Cabergoline; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Pituitary Neoplasms; Prolactinoma	2017
Korsakoff syndrome from retrochiasmatic suprasellar lesions: rapid reversal after relief of cerebral compression in 4 cases. Journal of neurosurgery, 2018, Volume: 128, Issue:6 Topics: Adenoma; Adult; Amnesia; Cabergoline; Cerebellar Diseases; Craniopharyngioma; Dopamine Antagonists; Humans; Korsakoff Syndrome; Male; Mammillary Bodies; Mental Disorders; Middle Aged; Nerve Compression Syndromes; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2018
Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death. Autophagy, 2017, Aug-03, Volume: 13, Issue:8 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Autophagosomes; Autophagy; Cabergoline; Cell Line, Tumor; Cell Proliferation; Ergolines; Humans; Mice, Nude; Pituitary Neoplasms; Rats; Reactive Oxygen Species; Receptors, Dopamine D5; Superoxide Dismutase; TOR Serine-Threonine Kinases	2017
An Overlooked Cause of Hypokalemia. The American journal of medicine, 2017, Volume: 130, Issue:10 Topics: 14-alpha Demethylase Inhibitors; Adenoma; Cabergoline; Cushing Syndrome; Dopamine Agonists; Ergolines; Female; Humans; Hypokalemia; Ketoconazole; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms	2017
Pregnancy and Tumor Outcomes in Women with Prolactinoma. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2017, Volume: 125, Issue:10 Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Outcome Assessment, Health Care; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Retrospective Studies; Young Adult	2017
An unusual case of Cushing's syndrome due to bihormonal ACTH-prolactin secreting pituitary macroadenoma with rapid response to cabergoline. BMJ case reports, 2017, Aug-07, Volume: 2017 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Young Adult	2017
Prolactinoma in a Dog. Veterinary pathology, 2017, Volume: 54, Issue:6 Topics: Adenoma; Animals; Cabergoline; Dogs; Dopamine Agonists; Ergolines; Fatal Outcome; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Tomography Scanners, X-Ray Computed	2017
[A rare case of giant galactocele associated with prolactinoma]. The Pan African medical journal, 2017, Volume: 27 Topics: Adult; Antineoplastic Agents; Breast Cyst; Cabergoline; Ergolines; Female; Humans; Pituitary Neoplasms; Prolactinoma	2017
Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up. Hormone research in paediatrics, 2018, Volume: 89, Issue:1 Topics: Cabergoline; Child; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Follow-Up Studies; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma	2018
Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine. The Journal of clinical endocrinology and metabolism, 2017, 10-01, Volume: 102, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Cell Death; Cells, Cultured; Chloroquine; Ergolines; Female; Hep G2 Cells; Humans; Mice; Mice, Nude; Pituitary Neoplasms; Prolactinoma; Rats; Rats, Inbred F344; Xenograft Model Antitumor Assays	2017
Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma. International clinical psychopharmacology, 2018, Volume: 33, Issue:2 Topics: Adult; Cabergoline; Cognition; Dopamine Agonists; Drug Monitoring; Female; Humans; Hyperprolactinemia; Male; Mental Status and Dementia Tests; Pituitary Neoplasms; Prolactin; Prolactinoma; Treatment Outcome	2018
Large pituitary gland with an expanding lesion in the context of neurofibromatosis 1. BMJ case reports, 2017, Oct-25, Volume: 2017 Topics: Acromegaly; Adult; Antineoplastic Agents; Cabergoline; Central Nervous System Cysts; Ergolines; Female; Human Growth Hormone; Humans; Magnetic Resonance Imaging; Neurofibromatosis 1; Pituitary Gland; Pituitary Neoplasms	2017
Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective. BMJ case reports, 2017, Nov-03, Volume: 2017 Topics: Adult; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diagnosis, Differential; Dopamine Agonists; Ergolines; Fibrosis; Humans; Hypogonadism; Hypothyroidism; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Thyroxine; Tricuspid Valve Insufficiency	2017
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma. Endocrinologia, diabetes y nutricion, 2017, Volume: 64, Issue:10 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined Modality Therapy; Dacarbazine; Drug Substitution; Ergolines; Fatal Outcome; Headache; Humans; Hyperprolactinemia; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Proton Therapy; Temozolomide	2017
Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man. Boletin de la Asociacion Medica de Puerto Rico, 2016, Volume: 108, Issue:1 Topics: Adult; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Time Factors	2016
Ectopic Prolactinoma Presenting as Bacterial Meningitis: A Diagnostic Conundrum. World neurosurgery, 2018, Volume: 112 Topics: Cabergoline; Cerebrospinal Fluid Rhinorrhea; Diagnosis, Differential; Dopamine Agonists; Ergolines; Female; Humans; Meningitis, Bacterial; Middle Aged; Penicillin G; Pituitary Neoplasms; Prolactinoma; Streptococcus pneumoniae; Treatment Outcome	2018
Transnasal Transsphenoidal Elevation of Optic Chiasm in Secondary Empty Sella Syndrome Following Prolactinoma Treatment. World neurosurgery, 2018, Volume: 112 Topics: Cabergoline; Dopamine Agonists; Empty Sella Syndrome; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Optic Chiasm; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2018
Treatment complexities in psychosis associated with cabergoline treatment in patients having pituitary prolactinomas. Asian journal of psychiatry, 2018, Volume: 31 Topics: Adult; Cabergoline; Dopamine Agonists; Female; GABA Agents; Humans; Pituitary Neoplasms; Prolactinoma; Psychoses, Substance-Induced; Valproic Acid	2018
Medical Management of a Prolactinoma in a 15-Year-Old Girl. The Journal of pediatrics, 2018, Volume: 200 Topics: Adolescent; Biomarkers, Tumor; Cabergoline; Disease Management; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactin; Prolactinoma	2018
The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine. Endocrinology, 2018, 06-01, Volume: 159, Issue:6 Topics: Animals; Cabergoline; Cell Proliferation; Cells, Cultured; Dopamine; Down-Regulation; HEK293 Cells; Homeostasis; Humans; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Prolactinoma; Rats; Signal Transduction	2018
Atypical giant prolactinoma with frontal lobe manifestations. BMJ case reports, 2018, Sep-04, Volume: 2018 Topics: Aged; Cabergoline; Confusion; Dopamine Agonists; Female; Frontal Lobe; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Memory Disorders; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2018
Pituitary Apoplexy in Long-Term Cabergoline User During Thrombocytopenia Due to Chemotherapy for Chronic Myelocytic Leukemia. World neurosurgery, 2018, Volume: 120 Topics: Cabergoline; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Long-Term Care; Magnetic Resonance Imaging; Middle Aged; Neuroendoscopy; Pituitary Apoplexy; Pituitary Neoplasms; Prolactinoma; Thrombocytopenia; Tomography, X-Ray Computed	2018
Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas. Endocrine, 2018, Volume: 62, Issue:2 Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Drug Resistance, Neoplasm; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Failure; Tumor Burden; Young Adult	2018
Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours. Nature communications, 2018, 11-05, Volume: 9, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Animals; Cabergoline; Carcinogenesis; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Progression; Down-Regulation; Female; HEK293 Cells; Heterografts; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Phosphoproteins; Phosphorylation; Pituitary Neoplasms; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Long Noncoding; Up-Regulation	2018
Giant prolactinoma, germline BRCA1 mutation, and depression: a case report. Journal of medical case reports, 2018, Dec-06, Volume: 12, Issue:1 Topics: Adult; Antidepressive Agents; BRCA1 Protein; Cabergoline; Depressive Disorder; Dopamine Agonists; Female; Humans; Magnetic Resonance Imaging; Mutation; Pituitary Neoplasms; Prolactinoma	2018
Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas. The Journal of clinical endocrinology and metabolism, 2019, 06-01, Volume: 104, Issue:6 Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Everolimus; Humans; Hypophysectomy; Magnetic Resonance Imaging; Male; Mice; Off-Label Use; Pituitary Gland; Pituitary Neoplasms; Prolactinoma; Radiotherapy, Adjuvant; Reoperation; TOR Serine-Threonine Kinases; Treatment Outcome	2019
Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report. Journal of medical case reports, 2019, Jan-20, Volume: 13, Issue:1 Topics: Adult; Anticonvulsants; Cabergoline; Dopamine Agonists; Fatigue; Frontal Lobe; Humans; Hydrocortisone; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Status Epilepticus; Thyroxine; Treatment Outcome; Vision Disorders	2019
Diagnostics and treatment of acromegaly - updated recommendations of the Polish Society of Endocrinology. Endokrynologia Polska, 2019, Volume: 70, Issue:1 Topics: Acromegaly; Cabergoline; Endocrinology; Female; Human Growth Hormone; Humans; Male; Pituitary Neoplasms; Poland; Societies, Medical; Somatostatin	2019
Ectopic pituitary adenomas: common presentations of a rare entity. Pituitary, 2019, Volume: 22, Issue:4 Topics: Adult; Cabergoline; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies	2019
Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor. Anti-cancer drugs, 2019, Volume: 30, Issue:5 Topics: Antineoplastic Agents, Alkylating; Cabergoline; Combined Modality Therapy; Cytoreduction Surgical Procedures; Dopamine Agonists; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pituitary Neoplasms; Prognosis; Temozolomide	2019
Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively. Cell death & disease, 2019, 04-18, Volume: 10, Issue:5 Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Bromocriptine; Cabergoline; Cell Line, Tumor; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Female; Mice; Mice, Nude; Microtubule-Associated Proteins; Pituitary Neoplasms; Prolactinoma; Proto-Oncogene Proteins c-akt; Rats; RNA Interference; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases	2019
Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas. Hormones & cancer, 2019, Volume: 10, Issue:2-3 Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Postmenopause; Premenopause; Prolactin; Prolactinoma; Recurrence; Remission Induction; Retrospective Studies; Risk; Treatment Outcome; Young Adult	2019
Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure. World neurosurgery, 2019, Volume: 129 Topics: Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Sex Factors; Treatment Failure; Tumor Burden	2019
Phenotype and resistance patterns of 10 resistant prolactinomas. Endocrinologia, diabetes y nutricion, 2020, Volume: 67, Issue:3 Topics: Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Phenotype; Pituitary Neoplasms; Prolactinoma; Retrospective Studies	2020
Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report. Journal of medical case reports, 2019, Jun-16, Volume: 13, Issue:1 Topics: Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Middle Aged; Mirtazapine; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Psychotropic Drugs; Quetiapine Fumarate; Stroke; Treatment Outcome; Tumor Burden	2019
McCune Albright syndrome: an endocrine medley. BMJ case reports, 2019, Jul-15, Volume: 12, Issue:7 Topics: Adenoma; Bone Density Conservation Agents; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Female; Fibrous Dysplasia, Polyostotic; Humans; Hyperthyroidism; Leg; Musculoskeletal Pain; Pituitary Neoplasms; Rare Diseases; Young Adult; Zoledronic Acid	2019
Start low, go slowly - mental abnormalities in young prolactinoma patients under cabergoline therapy. Journal of pediatric endocrinology & metabolism : JPEM, 2019, Sep-25, Volume: 32, Issue:9 Topics: Adolescent; Cabergoline; Child; Child, Preschool; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Germany; Humans; Incidence; Male; Mental Disorders; Pituitary Neoplasms; Prognosis; Prolactinoma; Retrospective Studies	2019
Transsphenoidal microsurgical results of female patients with prolactinomas. Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:9 Topics: Adult; Cabergoline; Cavernous Sinus; Dopamine Agonists; Endoscopy; Ergolines; Female; Humans; Magnetic Resonance Imaging; Microsurgery; Neoplasm Recurrence, Local; Neurosurgical Procedures; Pituitary Neoplasms; Postoperative Complications; Pregnancy; Prolactin; Prolactinoma; Retrospective Studies; Sphenoid Bone; Treatment Outcome	2013
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clinical endocrinology, 2013, Volume: 79, Issue:6 Topics: Adiposity; Adult; Blood Glucose; Body Mass Index; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Insulin Resistance; Lipids; Male; Metabolome; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Waist Circumference; Young Adult	2013
[Recurrent left sided sinusitis with hearing loss and occipital headache]. Laryngo- rhino- otologie, 2013, Volume: 92, Issue:5 Topics: Adult; Cabergoline; Diagnosis, Differential; Dopamine Antagonists; Epistaxis; Ergolines; Headache Disorders; Hearing Loss, High-Frequency; Hearing Loss, Sensorineural; Hearing Loss, Unilateral; Humans; Magnetic Resonance Imaging; Male; Nasal Obstruction; Pituitary Neoplasms; Prolactinoma; Sinusitis; Tinnitus; Tomography, X-Ray Computed	2013
Male prolactinomas presenting with normal testosterone levels. Pituitary, 2014, Volume: 17, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Cabergoline; Cohort Studies; Ergolines; Humans; Hypogonadism; Male; Middle Aged; Pituitary Neoplasms; Prognosis; Prolactinoma; Testosterone; Treatment Outcome	2014
Impressive shrinkage of a giant prolactinoma treated with cabergoline in a prepubescent girl. What now? Neuro endocrinology letters, 2013, Volume: 34, Issue:4 Topics: Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Induction Chemotherapy; Menarche; Pituitary Neoplasms; Prolactinoma; Tumor Burden	2013
The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma. Journal of pediatric endocrinology & metabolism : JPEM, 2014, Volume: 27, Issue:1-2 Topics: Adolescent; Anemia, Hemolytic; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Pituitary Neoplasms; Prolactinoma	2014
[Abnormalities of carbohydrate metabolism in acromegaly]. Medicina clinica, 2013, Nov-16, Volume: 141, Issue:10 Topics: Acromegaly; Adult; Aged; Blood Glucose; Body Mass Index; Cabergoline; Combined Modality Therapy; Cranial Irradiation; Cross-Sectional Studies; Ergolines; Female; Glucose; Glycated Hemoglobin; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hyperglycemia; Hypophysectomy; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Retrospective Studies; Somatostatin; Tumor Burden	2013
[Management of prolactinoma]. Revue medicale suisse, 2013, Aug-28, Volume: 9, Issue:395 Topics: Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma; Radiotherapy, Adjuvant	2013
The role of primary pharmacological therapy in acromegaly. Pituitary, 2014, Volume: 17 Suppl 1 Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Ergolines; Human Growth Hormone; Humans; Male; Octreotide; Pituitary Neoplasms; Somatostatin; Young Adult	2014
Thyrotropin-secreting pituitary tumor presenting with congestive heart failure and good response to dopaminergic agonist cabergoline. Journal of the Formosan Medical Association = Taiwan yi zhi, 2013, Volume: 112, Issue:11 Topics: Aged; Cabergoline; Dopamine Agonists; Ergolines; Follow-Up Studies; Heart Failure; Humans; Male; Pituitary Neoplasms; Thyrotropin	2013
Pituitary carcinoma with fourth ventricle metastasis: treatment by excision and Gamma-knife radiosurgery. Pituitary, 2014, Volume: 17, Issue:6 Topics: Cabergoline; Cerebral Ventricle Neoplasms; Dopamine Agonists; Ergolines; Fourth Ventricle; Humans; Male; Pituitary Hormones; Pituitary Neoplasms; Prolactinoma; Radiosurgery; Young Adult	2014
Prolactinoma-associated headache and dopamine agonist treatment. Cephalalgia : an international journal of headache, 2014, Volume: 34, Issue:7 Topics: Adult; Aminoquinolines; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Headache; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Recurrence; Substance Withdrawal Syndrome	2014
Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology, 2013, Volume: 98, Issue:4 Topics: Adiposity; Adult; Antineoplastic Agents; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Fasting; Female; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Male; Metabolic Diseases; Metabolic Syndrome; Pituitary Neoplasms; Prevalence; Prognosis; Prolactin; Prolactinoma; Prospective Studies; Time Factors; Treatment Outcome	2013
Pons herniation into skull base after cabergoline therapy of giant prolactinoma. Pituitary, 2015, Volume: 18, Issue:1 Topics: Antineoplastic Agents; Cabergoline; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Pons; Prolactinoma	2015
Women with prolactinomas presented at the postmenopausal period. Endocrine, 2014, Volume: 47, Issue:3 Topics: Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Luteinizing Hormone; Middle Aged; Pituitary Neoplasms; Postmenopause; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome	2014
Young female with acromegaloid features and pituitary macroadenoma: what is your diagnosis? Boletin de la Asociacion Medica de Puerto Rico, 2014, Volume: 106, Issue:1 Topics: Acanthosis Nigricans; Acromegaly; Adult; Bromocriptine; Cabergoline; Diagnosis, Differential; Ergolines; Female; Gastrointestinal Diseases; Hirsutism; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prognathism; Prolactinoma	2014
A case of iatrogenic severe mitral regurgitation. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2013, Volume: 80, Issue:3 Topics: Antineoplastic Agents; Bromocriptine; Cabergoline; Drug Therapy, Combination; Ergolines; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hormone Antagonists; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2013
Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy. Andrologia, 2015, Volume: 47, Issue:6 Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Estrogens; Female; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Transgender Persons	2015
Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases. Pituitary, 2015, Volume: 18, Issue:3 Topics: Adult; Antineoplastic Agents; Arabs; Biomarkers, Tumor; Cabergoline; Comorbidity; Ergolines; Female; Humans; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Saudi Arabia; Tertiary Care Centers; Time Factors; Treatment Outcome; Tumor Burden; Young Adult	2015
Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2014, Volume: 46, Issue:13 Topics: Adult; Cabergoline; Ergolines; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pituitary Neoplasms; Prolactin; Prolactinoma; Treatment Outcome	2014
[Pituitary apoplexy in a young woman]. Ugeskrift for laeger, 2014, Apr-22, Volume: 176, Issue:17 Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Apoplexy; Pituitary Neoplasms	2014
Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas. Neurological research, 2015, Volume: 37, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Young Adult	2015
Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. Clinical endocrinology, 2015, Volume: 82, Issue:5 Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Receptors, Dopamine D2; RNA, Messenger; Treatment Outcome	2015
Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology, 2015, Volume: 101, Issue:1 Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Hormone Replacement Therapy; Humans; Hyperprolactinemia; Male; Metabolome; Middle Aged; Pituitary Neoplasms; Prolactinoma; Testosterone	2015
[Pituitary apoplexy in a pregnant woman with cystic microprolactinoma]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2015, Volume: 62, Issue:4 Topics: Adult; Bromocriptine; Cabergoline; Combined Modality Therapy; Contraindications; Dopamine Agonists; Drug Substitution; Ergolines; Female; Headache; Hormone Replacement Therapy; Humans; Hydrocortisone; Hypophysectomy; Infant, Newborn; Male; Pituitary Apoplexy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prolactinoma; Thyroxine; Vision Disorders	2015
Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey. Neuro endocrinology letters, 2015, Volume: 36, Issue:1 Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Follow-Up Studies; Humans; Male; Optic Chiasm; Pituitary Neoplasms; Prolactinoma; Treatment Outcome; Vision, Low	2015
Prolactin serum concentrations after electroconvulsive therapy in a depressed patient with cabergoline-treated prolactinoma: implications for treatment. The journal of ECT, 2015, Volume: 31, Issue:2 Topics: Antidepressive Agents; Antineoplastic Agents; Cabergoline; Depressive Disorder, Major; Electroconvulsive Therapy; Ergolines; Female; Humans; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma	2015
SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015, Volume: 21, Issue:11 Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Cabergoline; Cohort Studies; Down-Regulation; Ergolines; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prognosis; Prolactin; Prolactinoma; Remission Induction; Time Factors; Tumor Burden; Young Adult	2015
Cabergoline for Cushing's disease: A case report. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2015, Volume: 62, Issue:10 Topics: Adrenocorticotropic Hormone; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Magnetic Resonance Imaging; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Remission Induction; Tumor Burden	2015
Does DRD2 polymorphism influence the clinical characteristics of prolactinoma? Annales d'endocrinologie, 2015, Volume: 76, Issue:5 Topics: Adult; Alleles; Antineoplastic Agents; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Genotype; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prolactin; Prolactinoma; Receptors, Dopamine D2	2015
Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States. World neurosurgery, 2016, Volume: 87 Topics: Adult; Aged; Bromocriptine; Cabergoline; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Ergolines; Female; Health Care Costs; Hormone Antagonists; Humans; Hyperprolactinemia; Life Expectancy; Male; Medicare; Microsurgery; Middle Aged; Monte Carlo Method; Neuroendoscopy; Pituitary Neoplasms; Prolactinoma; Quality-Adjusted Life Years; Sphenoid Sinus; Time Factors; Treatment Outcome; United States	2016
A man with breast discharge and headache. European journal of internal medicine, 2016, Volume: 29 Topics: Adult; Brain; Cabergoline; Dopamine Agonists; Erectile Dysfunction; Ergolines; Headache; Humans; Magnetic Resonance Imaging; Male; Nipple Discharge; Pituitary Neoplasms; Prolactinoma	2016
Macular amyloidosis complicating macroprolactinoma--a novel clinical association. Endokrynologia Polska, 2015, Volume: 66, Issue:6 Topics: Adrenal Insufficiency; Adult; Amyloidosis, Familial; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Macula Lutea; Male; Pituitary Neoplasms; Prolactinoma; Retinal Diseases; Skin Diseases, Genetic	2015
Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma. Anatolian journal of cardiology, 2016, Volume: 16, Issue:6 Topics: Adolescent; Adult; Atherosclerosis; Brachial Artery; Cabergoline; Carotid Intima-Media Thickness; Cross-Sectional Studies; Ergolines; Female; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Young Adult	2016
Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when? Pituitary, 2016, Volume: 19, Issue:3 Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Time Factors; Tumor Burden; Young Adult	2016
Mean platelet volume in patients with prolactinoma. Archives of endocrinology and metabolism, 2016, Volume: 60, Issue:4 Topics: Adolescent; Adult; Biomarkers, Tumor; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Reference Values; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult	2016
Prolactinomas: evolution after menopause. Archives of endocrinology and metabolism, 2016, Volume: 60, Issue:1 Topics: Adenoma; Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Withholding Treatment	2016
Chronic cluster headache and the pituitary gland. The journal of headache and pain, 2016, Volume: 17 Topics: Adenoma; Cabergoline; Central Nervous System Cysts; Cluster Headache; Diagnosis, Differential; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Sumatriptan; Treatment Outcome; Verapamil	2016
Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma. The American journal of case reports, 2016, 03-13, Volume: 17 Topics: Adult; Bone Diseases, Metabolic; Cabergoline; Dopamine Agonists; Ergolines; Glucose Intolerance; Humans; Hypertriglyceridemia; Male; Overweight; Pituitary Neoplasms; Prolactinoma	2016
Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:8 Topics: Adrenocorticotropic Hormone; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Hyperprolactinemia; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Prolactin; Prolactinoma	2016
Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary, 2016, Volume: 19, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Child; Ergolines; Female; Galactorrhea; Headache; Hormone Antagonists; Humans; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Sexual Dysfunction, Physiological; Treatment Outcome; Tumor Burden; Vision Disorders; Young Adult	2016
Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. European journal of endocrinology, 2016, Volume: 175, Issue:1 Topics: Adenoma; Adult; Aged; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Receptors, Dopamine; Receptors, Estrogen; Treatment Outcome	2016
Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. Journal of endocrinological investigation, 2016, Volume: 39, Issue:12 Topics: Adult; Aged; Biomarkers; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prognosis; Prolactinoma; Tomography, X-Ray Computed; Withholding Treatment	2016
Spontaneous subarachnoid hemorrhage due to ruptured cavernous internal carotid artery aneurysm after medical prolactinoma treatment. Journal of neurointerventional surgery, 2017, Volume: 9, Issue:3 Topics: Aneurysm, Ruptured; Cabergoline; Carotid Artery Diseases; Carotid Artery, Internal; Cavernous Sinus; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Skull Base; Subarachnoid Hemorrhage; Treatment Outcome	2017
Evaluaton of therapy with cabergoline in men with macroprolactinoa. Pomeranian journal of life sciences, 2015, Volume: 61, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Poland; Prolactinoma; Young Adult	2015
Topiramate Overcoming Dopamine Agonist-Induced Migraine Exacerbation and Avoiding Transsphenoidal Surgery in a Young Boy With a Macroprolactinoma. Headache, 2016, Volume: 56, Issue:9 Topics: Brain; Cabergoline; Central Nervous System Agents; Child; Dopamine Agonists; Ergolines; Fructose; Humans; Male; Migraine Disorders; Pituitary Neoplasms; Prolactinoma; Topiramate	2016
[Serum concentrations of glucose, cholesterol and triglycerides in men with prolactinoma treated with cabergoline]. Medicina clinica, 2016, Nov-18, Volume: 147, Issue:10 Topics: Adult; Antineoplastic Agents; Biomarkers; Blood Glucose; Cabergoline; Cholesterol; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Treatment Outcome; Triglycerides	2016
Prolactinomas may have unusual presentations resulting from massive extrasellar tumor extension. Arquivos de neuro-psiquiatria, 2016, Volume: 74, Issue:7 Topics: Adolescent; Adult; Antineoplastic Agents; Cabergoline; Cerebrospinal Fluid Leak; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Sella Turcica; Time Factors; Treatment Outcome; Tumor Burden; Young Adult	2016
Cabergoline can induce mania with psychotic features in bipolar I disorder: a case report. Asian journal of psychiatry, 2016, Volume: 22 Topics: Adult; Antineoplastic Agents; Bipolar Disorder; Cabergoline; Ergolines; Female; Humans; Pituitary Neoplasms; Prolactinoma; Psychoses, Substance-Induced	2016
Sellar Wegener Granulomatosis Masquerading as Cabergoline-Resistant Prolactinoma. World neurosurgery, 2016, Volume: 95 Topics: Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Drug Resistance, Neoplasm; Ergolines; Female; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Pituitary Neoplasms; Prolactinoma; Rituximab; Sella Turcica	2016
Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metabolic brain disease, 2017, Volume: 32, Issue:1 Topics: Adult; Cabergoline; Cholesterol; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Lipoproteins, HDL; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2017
Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment. World neurosurgery, 2016, Volume: 95 Topics: Adolescent; Antineoplastic Agents; Cabergoline; Disease Progression; Drug Resistance, Neoplasm; Ergolines; Ganglioneuroma; Humans; Hydrocephalus; Magnetic Resonance Imaging; Male; Neoplasms, Complex and Mixed; Neuroendoscopy; Pituitary Neoplasms; Prolactinoma	2016
Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine, 2017, Volume: 55, Issue:2 Topics: Adult; Aged; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hypogonadism; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Sexual Dysfunction, Physiological	2017
Long-term outcome of macroprolactinomas. Annales d'endocrinologie, 2016, Volume: 77, Issue:6 Topics: Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; France; Humans; Hyperprolactinemia; Hypopituitarism; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Treatment Outcome; Young Adult	2016
SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:1 Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Remission Induction; Retrospective Studies; Treatment Failure; Treatment Outcome; Tumor Burden; Young Adult	2017
10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine, 2017, Volume: 55, Issue:1 Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Young Adult	2017
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. Endocrine, 2017, Volume: 55, Issue:1 Topics: Adult; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Prospective Studies; Treatment Outcome; Young Adult	2017
Low Testosterone in Men Should Be a Sign Rather Than a Number to Increase: A Teachable Moment. JAMA internal medicine, 2016, 12-01, Volume: 176, Issue:12 Topics: Cabergoline; Dopamine Agonists; Ergolines; Eunuchism; Hormone Replacement Therapy; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Testosterone	2016
Management of prolactinomas: a survey of physicians from the Middle East and North Africa. Pituitary, 2017, Volume: 20, Issue:2 Topics: Adult; Africa, Northern; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Middle East; Physicians; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma; Surveys and Questionnaires	2017
SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:3 Topics: Adult; Amino Acids; Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Cabergoline; Cross-Sectional Studies; Ergolines; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Middle Aged; Osteocalcin; Osteoprotegerin; Pituitary Neoplasms; Prolactinoma; Prospective Studies; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Vitamin D	2017
Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2017, Volume: 33, Issue:4 Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Infertility, Female; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Treatment Outcome; Young Adult	2017
Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes. Obstetrics and gynecology, 2017, Volume: 129, Issue:1 Topics: Adenoma; Adult; Amenorrhea; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cesarean Section; Dopamine Agonists; Ergolines; Female; Galactorrhea; Humans; Incidence; Pituitary Neoplasms; Pre-Eclampsia; Preconception Care; Pregnancy; Pregnancy Complications, Neoplastic; Premature Birth; Prolactinoma; Prospective Studies; Stillbirth; United Kingdom; Vision Disorders; Young Adult	2017
MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. European journal of endocrinology, 2017, Volume: 176, Issue:3 Topics: Adult; Aminoquinolines; Belgium; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; France; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies	2017
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocrine-related cancer, 2008, Volume: 15, Issue:2 Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Cabergoline; Cell Division; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Female; Fibroblasts; Humans; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; RNA, Messenger; Somatostatin; Sulpiride; Thymidine; Tritium; Tumor Cells, Cultured	2008
Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:9 Topics: Adult; Aortic Valve; Cabergoline; Calcinosis; Case-Control Studies; Cross-Sectional Studies; Disease Progression; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Time Factors; Tricuspid Valve Insufficiency	2008
Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clinical endocrinology, 2009, Volume: 70, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Male; Middle Aged; Optic Chiasm; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Vision Disorders; Visual Fields; Young Adult	2009
Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:10 Topics: Adult; Antineoplastic Agents; Cabergoline; Case-Control Studies; Chronic Disease; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Time Factors; Tricuspid Valve Insufficiency; Ultrasonography	2008
Misdiagnosis due to the hook effect in prolactin assay. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2008, Volume: 17, Issue:5 Topics: Antineoplastic Agents; Cabergoline; Diabetes Insipidus, Neurogenic; Diagnostic Errors; Ergolines; Female; Glucocorticoids; Humans; Hypopituitarism; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prednisolone; Prolactin; Prolactinoma; Thyroxine	2008
Pituitary apoplexy within a macroprolactinoma. Nature clinical practice. Endocrinology & metabolism, 2008, Volume: 4, Issue:11 Topics: Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Ergolines; Female; Humans; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Middle Aged; Pituitary Apoplexy; Pituitary Neoplasms; Prolactin; Prolactinoma; Tomography, X-Ray Computed	2008
High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy. Clinical endocrinology, 2009, Volume: 70, Issue:5 Topics: Adult; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Infant, Newborn; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma	2009
[Some issues in the diagnosis and treatment of hyperprolactinemia]. Zhonghua fu chan ke za zhi, 2008, Volume: 43, Issue:4 Topics: Aminoquinolines; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Pituitary Gland; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma	2008
The cabergoline-resistant prolactinoma patient: new challenges. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:12 Topics: Adult; Cabergoline; Dopamine Agonists; Drug Resistance; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine; Young Adult	2008
Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. Pituitary, 2011, Volume: 14, Issue:4 Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Male; Octreotide; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2011
Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers. Endocrine pathology, 2009,Spring, Volume: 20, Issue:1 Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cabergoline; Drug Resistance, Neoplasm; Ergolines; Humans; Hypothyroidism; Immunohistochemistry; Magnetic Resonance Imaging; Male; Neovascularization, Pathologic; Pituitary Neoplasms; Prolactin; Prolactinoma	2009
Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. European journal of endocrinology, 2009, Volume: 160, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Failure; Young Adult	2009
Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. The Medical journal of Australia, 2009, Jan-19, Volume: 190, Issue:2 Topics: Antineoplastic Agents; Cabergoline; Ergolines; Gambling; Humans; Libido; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma	2009
Macroprolactinomas presenting as nasal polyps: a series of three cases. Irish journal of medical science, 2012, Volume: 181, Issue:2 Topics: Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Diagnostic Errors; Ergolines; Humans; Male; Middle Aged; Nasal Polyps; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin	2012
Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Prolactinoma; Recurrence; Retrospective Studies; Time Factors; Withholding Treatment; Young Adult	2009
McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report. Arquivos brasileiros de endocrinologia e metabologia, 2009, Volume: 53, Issue:1 Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents, Hormonal; Cabergoline; Ergolines; Facial Bones; Female; Fibrous Dysplasia, Polyostotic; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Octreotide; Pituitary Neoplasms; Skull	2009
Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma. Pituitary, 2011, Volume: 14, Issue:4 Topics: Adult; Cabergoline; Dopamine Agonists; Encephalocele; Ergolines; Humans; Male; Optic Chiasm; Pituitary Neoplasms; Prolactinoma; Sella Turcica; Tumor Burden	2011
Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma. Internal medicine journal, 2009, Volume: 39, Issue:4 Topics: Brain Ischemia; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Fatal Outcome; Fibrosis; Heart Valve Prosthesis Implantation; Humans; Intestinal Obstruction; Male; Middle Aged; Mitral Valve Insufficiency; Pituitary Neoplasms; Prolactinoma; Tricuspid Valve Insufficiency; Ventricular Dysfunction, Left	2009
Cabergoline resistance in pediatric prolactinomas. Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:5 Topics: Adolescent; Antineoplastic Agents; Cabergoline; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Male; Pituitary Neoplasms; Prolactinoma	2009
Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clinical endocrinology, 2010, Volume: 72, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Case-Control Studies; Echocardiography; Ergolines; Female; Heart Valves; Hormone Antagonists; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Sex Characteristics; Young Adult	2010
Non-surgical management of cystic prolactinomas. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2009, Volume: 16, Issue:11 Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Follow-Up Studies; Gadolinium; Hormones; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Young Adult	2009
Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. Journal of Korean medical science, 2009, Volume: 24, Issue:5 Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies	2009
Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:2 Topics: Adenoma; Aged; Apoptosis; Cabergoline; Cell Line, Tumor; Cell Survival; Ergolines; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Pituitary Neoplasms; Receptors, Somatostatin; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Somatostatin; Vascular Endothelial Growth Factor A	2010
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern? Expert review of cardiovascular therapy, 2010, Volume: 8, Issue:1 Topics: Adult; Cabergoline; Case-Control Studies; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2	2010
Pituitary gland: can prolactinomas be cured medically? Nature reviews. Endocrinology, 2010, Volume: 6, Issue:4 Topics: Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Meta-Analysis as Topic; Pituitary Gland; Pituitary Neoplasms; Prolactinoma; Recurrence; Withholding Treatment	2010
Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:6 Topics: Adult; Birth Weight; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Progesterone; Prolactin; Prolactinoma	2010
Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clinical endocrinology, 2010, Volume: 73, Issue:2 Topics: Adult; Antineoplastic Agents; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infant, Newborn; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Prolactinoma; Retrospective Studies	2010
Prolactinomas and pregnancy. Clinical endocrinology, 2010, Volume: 73, Issue:2 Topics: Aminoquinolines; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Embryonic Development; Ergolines; Female; Humans; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma	2010
Gender differences in macroprolactinomas: study of clinical features, outcome of patients and ki-67 expression in tumor tissue. Frontiers of hormone research, 2010, Volume: 38 Topics: Adult; Age Factors; Cabergoline; Ergolines; Estradiol; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Sex Characteristics	2010
Resolution of third nerve palsy following treatment of prolactinoma with cabergoline. Acta neurochirurgica, 2010, Volume: 152, Issue:10 Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Male; Oculomotor Nerve; Oculomotor Nerve Diseases; Pituitary Neoplasms; Prolactinoma	2010
Cystic degeneration of macroprolactinoma on long-term cabergoline. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:8 Topics: Adult; Antineoplastic Agents; Cabergoline; Cerebrospinal Fluid Rhinorrhea; Ergolines; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Radiography; Treatment Outcome	2010
Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary, 2011, Volume: 14, Issue:1 Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Child; Dopamine Agents; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Young Adult	2011
Two diagnostic pitfalls mimicking a prolactin-secreting microadenoma. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:12 Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Diagnostic Errors; Ergolines; Female; Galactorrhea; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Menstruation Disturbances; Pituitary Neoplasms; Prolactin	2010
Transsphenoidal treatment of secondary empty sella syndrome using low field strength intraoperative MRI: case report. Minimally invasive neurosurgery : MIN, 2010, Volume: 53, Issue:4 Topics: Aged; Cabergoline; Empty Sella Syndrome; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactinoma; Treatment Outcome; Visual Fields	2010
Pituitary tumors: cabergoline versus bromocriptine: a meta-analysis? Nature reviews. Endocrinology, 2011, Volume: 7, Issue:5 Topics: Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Humans; Meta-Analysis as Topic; Pituitary Neoplasms; Treatment Outcome	2011
Giant prolactinoma causing cranio-cervical junction instability: a case report. British journal of neurosurgery, 2011, Volume: 25, Issue:6 Topics: Adult; Antineoplastic Agents; Arthrodesis; Cabergoline; Cervical Vertebrae; Cranial Fossa, Posterior; Cranial Nerve Diseases; Craniotomy; Ergolines; Humans; Hyperprolactinemia; Joint Instability; Magnetic Resonance Imaging; Male; Neoplasm Invasiveness; Occipital Bone; Orthotic Devices; Pituitary Neoplasms; Prolactinoma; Recovery of Function; Treatment Outcome	2011
Chronic anemia as first clinical manifestation of a prolactin-secreting pituitary macroadenoma in a male patient. The American journal of medicine, 2011, Volume: 124, Issue:6 Topics: Anemia; Antineoplastic Agents; Biomarkers, Tumor; Cabergoline; Chronic Disease; Dopamine Agonists; Drug Therapy, Combination; Early Detection of Cancer; Ergolines; Hematocrit; Hemoglobins; Hormone Replacement Therapy; Humans; Hydrocortisone; Hypogonadism; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone; Thyroxine; Treatment Outcome	2011
[Complications of treatment of prolactinoma by dopamine agonists]. Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko, 2011, Volume: 75, Issue:2 Topics: Adolescent; Adult; Cabergoline; Cerebrospinal Fluid Rhinorrhea; Dopamine Agonists; Ergolines; Humans; Intracranial Hemorrhages; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Radiography; Treatment Outcome; Vision Disorders; Young Adult	2011
[Pathological gambling induced by dopamine agonists]. Fortschritte der Neurologie-Psychiatrie, 2011, Volume: 79, Issue:8 Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Gambling; Humans; Indoles; International Classification of Diseases; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Restless Legs Syndrome	2011
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. Clinical endocrinology, 2012, Volume: 76, Issue:3 Topics: Adenoma; Adult; Cabergoline; Cell Proliferation; Dopamine; Dopamine Agonists; Drug Synergism; Ergolines; Gene Expression; Humans; Immunohistochemistry; Male; Octreotide; Pituitary Neoplasms; Protein Isoforms; Receptors, Dopamine D2; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; Somatostatin; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine; Tumor Cells, Cultured	2012
Extralabel use of cabergoline in the treatment of a pituitary adenoma in a rat. Journal of the American Veterinary Medical Association, 2011, Sep-01, Volume: 239, Issue:5 Topics: Adenoma; Animals; Antineoplastic Agents; Cabergoline; Ergolines; Male; Pets; Pituitary Neoplasms; Rats; Rodent Diseases	2011
Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline. The Indian journal of medical research, 2011, Volume: 134 Topics: Analysis of Variance; Cabergoline; Enzyme-Linked Immunosorbent Assay; Ergolines; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hypothalamo-Hypophyseal System; Luteinizing Hormone; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Radioimmunoassay; Sperm Count; Sperm Motility; Testis; Testosterone; Time Factors	2011
[Prolactinoma treatment status in the cabergoline era]. No shinkei geka. Neurological surgery, 2011, Volume: 39, Issue:11 Topics: Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma; Treatment Outcome	2011
Acute shrinkage of a giant prolactinoma, masquerading as an erosive skull base tumour, with cabergoline. QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:1 Topics: Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Ergolines; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Skull Base Neoplasms	2013
[Cabergoline-induced tension pneumocephalus in a patient with giant invasive prolactinoma. Case report]. Neurocirugia (Asturias, Spain), 2011, Volume: 22, Issue:6 Topics: Antineoplastic Agents; Cabergoline; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Pneumocephalus; Prolactinoma; Tomography, X-Ray Computed	2011
Von Hippel-Lindau disease and aggressive GH-PRL pituitary adenoma in a young boy. Annales d'endocrinologie, 2012, Volume: 73, Issue:1 Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Human Growth Hormone; Humans; Magnetic Resonance Imaging; Male; Mutation; Pituitary Neoplasms; Prolactin; Somatostatin; Treatment Outcome; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein	2012
Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis. Gender medicine, 2012, Volume: 9, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Male; Obesity, Morbid; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones; Schizophrenia	2012
Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion. Molecular and cellular endocrinology, 2012, May-15, Volume: 355, Issue:1 Topics: Adenoviridae; Adolescent; Adult; Cabergoline; Dopamine; Dopamine Agonists; Ergolines; Female; Genetic Vectors; Humans; Male; Octreotide; Pituitary Neoplasms; Primary Cell Culture; Prolactin; Prolactinoma; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin; Transfection	2012
Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Pituitary, 2013, Volume: 16, Issue:1 Topics: Aged; Cabergoline; Cell Survival; Ergolines; Female; Humans; Male; Microscopy, Fluorescence; Middle Aged; Pituitary Neoplasms; Receptors, Dopamine; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2013
Spontaneous coronary artery dissection during cabergoline therapy. Texas Heart Institute journal, 2012, Volume: 39, Issue:1 Topics: Adult; Angina Pectoris; Antineoplastic Agents, Hormonal; Aortic Dissection; Cabergoline; Cardiovascular Agents; Coronary Aneurysm; Coronary Angiography; Coronary Vasospasm; Ergolines; Female; Humans; Pituitary Neoplasms; Predictive Value of Tests; Prolactinoma; Recurrence; Risk Factors; Time Factors; Treatment Outcome	2012
Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. European journal of endocrinology, 2012, Volume: 167, Issue:1 Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Prospective Studies	2012
Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas. Neuro endocrinology letters, 2012, Volume: 33, Issue:3 Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Retrospective Studies; Risk Factors; Ultrasonography; Young Adult	2012
Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. European journal of endocrinology, 2012, Volume: 167, Issue:3 Topics: Adult; Aged; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily D, Member 1; ATP-Binding Cassette Transporters; Cabergoline; Case-Control Studies; Ergolines; Fatigue; Female; Headache; Humans; Male; Mice; Mice, Knockout; Middle Aged; Pituitary Neoplasms; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prolactinoma; Treatment Outcome	2012
[Hyperprolactin as cause of hypoactive sexual desire in men]. Ugeskrift for laeger, 2012, Jun-18, Volume: 174, Issue:25 Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Libido; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Sexual Dysfunction, Physiological	2012
Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas. Pituitary, 2013, Volume: 16, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cabergoline; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Treatment Outcome; Young Adult	2013
Disappearance of pituitary macro adenoma with combination of ketoconazole and cabergoline treatment: an unusual case of Cushing's syndrome with interesting findings. BMJ case reports, 2012, Jul-03, Volume: 2012 Topics: 14-alpha Demethylase Inhibitors; Adenoma; Adult; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Diagnosis, Differential; Drug Therapy, Combination; Ergolines; Humans; Ketoconazole; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Severity of Illness Index; Tomography, X-Ray Computed	2012
Cabergoline-induced pneumocephalus in a medically treated macroprolactinoma. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:10 Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Pituitary Neoplasms; Pneumocephalus; Prolactinoma	2012
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European journal of endocrinology, 2012, Volume: 167, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Chemotherapy, Adjuvant; Child; Drug Administration Schedule; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation; Pituitary Neoplasms; Prolactinoma; Proto-Oncogene Proteins; Retrospective Studies; Treatment Failure	2012
Medically treated prolactin-secreting pituitary adenomas: when should we operate? British journal of neurosurgery, 2013, Volume: 27, Issue:1 Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Hormone Antagonists; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Postmenopause; Premenopause; Prolactinoma; Prospective Studies; Retrospective Studies; Sphenoid Bone; Time Factors; Treatment Failure	2013
Cabergoline therapy for macroprolactinoma during pregnancy: a case report. BMC research notes, 2012, Oct-31, Volume: 5 Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma	2012
Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:1 Topics: Adult; Antineoplastic Agents; Breast Feeding; Cabergoline; Data Collection; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Lactation; Observation; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Puerperal Disorders; Recurrence; Time Factors	2013
Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas. Pituitary, 2013, Volume: 16, Issue:4 Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Thromboembolism; Young Adult	2013
Cabergoline-induced psychosis in a patient with undiagnosed depression. The Journal of neuropsychiatry and clinical neurosciences, 2012,Fall, Volume: 24, Issue:4 Topics: Adult; Cabergoline; Depressive Disorder; Ergolines; Female; Humans; Pituitary Neoplasms; Prolactinoma; Psychoses, Substance-Induced	2012
Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy. Future oncology (London, England), 2012, Volume: 8, Issue:12 Topics: Adolescent; Aminoquinolines; Cabergoline; Dopamine Agonists; Ergolines; Exophthalmos; Humans; Hydrocephalus; Male; Pituitary Neoplasms; Prolactin; Prolactinoma	2012
Hyperprolactinemia: an unusual cause of erectile dysfunction. Archives of sexual behavior, 2013, Volume: 42, Issue:3 Topics: Adenoma; Adult; Cabergoline; Dopamine Agonists; Erectile Dysfunction; Ergolines; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Treatment Outcome	2013
Hyperprolactinemia in children: clinical features and long-term results. Journal of pediatric endocrinology & metabolism : JPEM, 2012, Volume: 25, Issue:11-12 Topics: Adolescent; Bromocriptine; Cabergoline; Child; Combined Modality Therapy; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Treatment Outcome	2012
Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary, 2001, Volume: 4, Issue:3 Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma	2001
The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:10 Topics: Adult; Anastrozole; Aromatase Inhibitors; Bromocriptine; Cabergoline; Dopamine Agonists; Enzyme Inhibitors; Ergolines; Hormone Replacement Therapy; Humans; Magnetic Resonance Imaging; Male; Nitriles; Pituitary Neoplasms; Prolactin; Prolactinoma; Sexual Dysfunction, Physiological; Testosterone; Treatment Outcome; Triazoles	2002
Effect of cabergoline on thyroid function in hyperprolactinaemia. Clinical endocrinology, 2002, Volume: 57, Issue:5 Topics: Cabergoline; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Thyrotropin; Thyroxine	2002
Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:11 Topics: Adenoma; Antineoplastic Agents; Body Height; Cabergoline; DNA Mutational Analysis; Ergolines; Fibrous Dysplasia, Polyostotic; GTP-Binding Protein alpha Subunits, Gs; Human Growth Hormone; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Octreotide; Pituitary Neoplasms	2002
Prolactinomas, dopamine agonists and headache: two case reports. European journal of neurology, 2003, Volume: 10, Issue:2 Topics: Adult; Amenorrhea; Anti-Inflammatory Agents, Non-Steroidal; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Headache; Humans; Indomethacin; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactin; Prolactinoma; Radiography	2003
[Efficacy of cabergoline in the treatment of macroprolactinoma]. Presse medicale (Paris, France : 1983), 2003, Jan-18, Volume: 32, Issue:2 Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Time Factors	2003
[Macroadenoma of the pituitary gland with moderate hyperprolactinaemia]. Deutsche medizinische Wochenschrift (1946), 2003, Mar-28, Volume: 128, Issue:13 Topics: Cabergoline; Diagnosis, Differential; Ergolines; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Pituitary Gland; Pituitary Neoplasms; Postoperative Complications; Prolactinoma	2003
Giant prolactinomas in men: efficacy of cabergoline treatment. Clinical endocrinology, 2003, Volume: 58, Issue:5 Topics: Adrenal Glands; Adult; Aged; Antineoplastic Agents; Cabergoline; Erectile Dysfunction; Ergolines; Humans; Hypothyroidism; Libido; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Vision Disorders	2003
Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary, 2002, Volume: 5, Issue:4 Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; False Negative Reactions; Headache; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Pituitary Function Tests; Pituitary Neoplasms; Prolactin; Prolactinoma; Skull Base Neoplasms; Vision Disorders	2002
Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. The New England journal of medicine, 2003, Nov-20, Volume: 349, Issue:21 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Recurrence; Withholding Treatment	2003
[Clinical and therapeutic aspects of prolactinoma in men]. Arquivos de neuro-psiquiatria, 2003, Volume: 61, Issue:4 Topics: Adolescent; Adult; Age of Onset; Biomarkers; Bromocriptine; Cabergoline; Chi-Square Distribution; Dopamine Agonists; Ergolines; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Pituitary Neoplasms; Prolactin; Prolactinoma; Statistics, Nonparametric; Treatment Outcome	2003
Prolactinomas. The New England journal of medicine, 2004, Mar-04, Volume: 350, Issue:10 Topics: Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Prolactinoma; Withholding Treatment	2004
Prolactinomas. The New England journal of medicine, 2004, Mar-04, Volume: 350, Issue:10 Topics: Antineoplastic Agents; Cabergoline; Ergolines; Follow-Up Studies; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Prolactinoma; Recurrence; Withholding Treatment	2004
[Pharmacologic cure of a pituitary macroprolactinoma]. Ginecologia y obstetricia de Mexico, 2003, Volume: 71 Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma	2003
Increased serum concentration of nerve growth factor in patients with microprolactinoma. Neuropeptides, 2004, Volume: 38, Issue:1 Topics: Adult; Cabergoline; Dopamine Antagonists; Ergolines; Female; Humans; Immunoenzyme Techniques; Nerve Growth Factor; Pituitary Neoplasms; Prolactin; Prolactinoma; Stimulation, Chemical; Thyrotropin-Releasing Hormone	2004
Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:4 Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Protein Isoforms; Protein Subunits; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D4; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tumor Cells, Cultured; Visual Fields	2004
Prolactinoma presenting as painful postganglionic Horner syndrome. Neurology, 2004, Apr-27, Volume: 62, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Bromocriptine; Cabergoline; Carotid Arteries; Dopamine Agonists; Ergolines; Horner Syndrome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Migraine Disorders; Neoplasm Recurrence, Local; p-Hydroxyamphetamine; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction	2004
Dopamine receptor expression and function in corticotroph pituitary tumors. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:5 Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Pituitary Neoplasms; Radioligand Assay; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured	2004
Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapy. Age and ageing, 2004, Volume: 33, Issue:4 Topics: Adenoma; Aged; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hydrocephalus; Male; Pituitary Neoplasms; Prolactinoma	2004
Massive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised prolactinoma causing thoracic syringomyelia. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:10 Topics: Adult; Antineoplastic Agents; Brain Stem Neoplasms; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2004
[Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor]. Lakartidningen, 2004, Oct-07, Volume: 101, Issue:41 Topics: Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma	2004
Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Hormone research, 2004, Volume: 62, Issue:6 Topics: Adenoma; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Cyproheptadine; Dopamine Agonists; Ergolines; Female; Hormone Replacement Therapy; Humans; Magnetic Resonance Imaging; Nelson Syndrome; Pituitary Neoplasms	2004
Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary, 2004, Volume: 7, Issue:1 Topics: Acromegaly; Adult; Antineoplastic Agents; Biomarkers; Cabergoline; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Pituitary Gland; Pituitary Neoplasms; Prolactin	2004
Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma. Journal of endocrinological investigation, 2004, Volume: 27, Issue:11 Topics: Adenoma; Adrenocorticotropic Hormone; Cabergoline; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Receptors, Dopamine D2; Treatment Outcome	2004
Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma. Pituitary, 2004, Volume: 7, Issue:2 Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hypopituitarism; Magnetic Resonance Imaging; Male; Pituitary Diseases; Pituitary Neoplasms; Prolactin; Prolactinoma; Stroke	2004
Cabergoline decreases somatotroph adenoma size: a case report. Pituitary, 2004, Volume: 7, Issue:2 Topics: Adenoma; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cabergoline; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Pituitary Neoplasms; Treatment Outcome	2004
The clinical characteristics of headache in patients with pituitary tumours. Brain : a journal of neurology, 2005, Volume: 128, Issue:Pt 8 Topics: Adenoma; Adult; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Disability Evaluation; Dopamine Agonists; Ergolines; Female; Headache; Humans; Male; Migraine Disorders; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Severity of Illness Index; Somatostatin; Time Factors	2005
A case of postprandial cluster-like headache with prolactinoma: dramatic response to cabergoline. Headache, 2005, Volume: 45, Issue:5 Topics: Adolescent; Antineoplastic Agents; Cabergoline; Cluster Headache; Eating; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Recurrence; Treatment Outcome	2005
The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma. Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:6 Topics: Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2005
Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clinical endocrinology, 2005, Volume: 63, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome	2005
Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases. Pituitary, 2004, Volume: 7, Issue:3 Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Cabergoline; Combined Modality Therapy; Decompression, Surgical; Ergolines; Female; Humans; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Apoplexy; Pituitary Gland; Pituitary Neoplasms; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vision Disorders	2004
Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. American journal of physiology. Endocrinology and metabolism, 2005, Volume: 289, Issue:6 Topics: Acromegaly; Cabergoline; Cell Division; Cell Line, Tumor; Dopamine; Ergolines; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor II; Lung Neoplasms; Peptides, Cyclic; Pituitary Neoplasms; Receptors, Dopamine; Receptors, Somatostatin; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Somatostatin	2005
Severe digital vasospasm caused by cabergoline. Saudi medical journal, 2005, Volume: 26, Issue:7 Topics: Adult; Antineoplastic Agents; Cabergoline; Constriction, Pathologic; Ergolines; Female; Fingers; Humans; Peripheral Vascular Diseases; Pituitary Neoplasms; Prolactinoma	2005
Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatment. Journal of neuro-oncology, 2006, Volume: 76, Issue:1 Topics: Adult; Cabergoline; Dopamine Agonists; Drainage; Ergolines; Humans; Hydrocephalus; Intracranial Hypertension; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2006
Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary, 2005, Volume: 8, Issue:1 Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction; Retrospective Studies; Treatment Outcome	2005
A case of macroprolactinoma and elevated insulin-like growth factor-I in a young boy. Acta paediatrica (Oslo, Norway : 1992), 2005, Volume: 94, Issue:12 Topics: Antineoplastic Agents; Cabergoline; Child; Ergolines; Glucose Tolerance Test; Humans; Hypothyroidism; Insulin-Like Growth Factor I; Male; Pituitary Neoplasms; Prolactinoma	2005
The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clinical endocrinology, 2006, Volume: 64, Issue:3 Topics: Adult; Antineoplastic Agents; Cabergoline; Case-Control Studies; Drug Administration Schedule; Ergolines; Gonadotropins; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Semen; Sperm Count; Spermatozoa; Testosterone; Time Factors; Treatment Outcome	2006
Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clinical endocrinology, 2006, Volume: 64, Issue:4 Topics: Adult; Cabergoline; Carotid Artery, Internal; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Sphenoid Sinus; Treatment Outcome	2006
Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'. Journal of neuro-oncology, 2006, Volume: 79, Issue:1 Topics: Abducens Nerve Diseases; Cabergoline; Diagnosis, Differential; Diagnostic Errors; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Oculomotor Nerve Diseases; Pituitary Neoplasms; Prolactin; Prolactinoma; Skull Base Neoplasms; Trochlear Nerve Diseases	2006
Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy. Nature clinical practice. Endocrinology & metabolism, 2006, Volume: 2, Issue:3 Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma	2006
Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas. Fertility and sterility, 2006, Volume: 86, Issue:3 Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms	2006
Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? European journal of endocrinology, 2006, Volume: 155, Issue:5 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Aminoquinolines; Benzamides; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon	2006
Presentation of a functional pituitary adenoma as a significant decrease in prostate-specific antigen level in a patient followed for prostate cancer. The Canadian journal of urology, 2006, Volume: 13, Issue:6 Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Male; Neoplasms, Second Primary; Pituitary Neoplasms; Prolactinoma; Prostate-Specific Antigen; Prostatic Neoplasms	2006
Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma. Clinical endocrinology, 2007, Volume: 66, Issue:1 Topics: Adult; Cabergoline; Disease Progression; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Prolactinoma	2007
Reduced growth of beard as the only diagnostic sign in a patient with macroprolactinoma. Journal of the European Academy of Dermatology and Venereology : JEADV, 2007, Volume: 21, Issue:1 Topics: Adenoma; Adult; Cabergoline; Dopamine Agonists; Ergolines; Face; Hair; Humans; Hydrocortisone; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Testosterone; Thyroxine	2007
[Simultaneous defect of visual fields and loss of libido--a coincidence?]. Praxis, 2006, Dec-06, Volume: 95, Issue:49 Topics: Cabergoline; Diagnosis, Differential; Dopamine Agonists; Erectile Dysfunction; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Libido; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Compression Syndromes; Optic Nerve Diseases; Pituitary Neoplasms; Prolactinoma; Visual Fields	2006
SUNCT syndrome in a patient with prolactinoma and cabergoline-induced attacks. Cephalalgia : an international journal of headache, 2007, Volume: 27, Issue:1 Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Pituitary Neoplasms; Prolactinoma; SUNCT Syndrome	2007
[Predictive value of the Knosp classification in grading the surgical resection of invasive pituitary macroadenomas. A prospective study of 23 cases]. Neurocirugia (Asturias, Spain), 2006, Volume: 17, Issue:6 Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Cabergoline; Cavernous Sinus; Combined Modality Therapy; Cranial Irradiation; Diabetes Insipidus, Neurogenic; Dose Fractionation, Radiation; Endoscopy; Ergolines; Female; Follow-Up Studies; Humans; Hypophysectomy; Magnetic Resonance Imaging; Male; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pituitary Neoplasms; Postoperative Complications; Predictive Value of Tests; Prognosis; Prospective Studies; Radiography; Radiotherapy, Adjuvant; Somatostatin; Sphenoid Bone; Treatment Outcome	2006
Cerebrospinal fluid leakage as complication of treatment with cabergoline for macroprolactinomas. Journal of endocrinological investigation, 2006, Volume: 29, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Cabergoline; Cerebrospinal Fluid Rhinorrhea; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma	2006
Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. European journal of endocrinology, 2007, Volume: 156, Issue:2 Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Time Factors; Treatment Outcome; Vision Disorders; Visual Fields	2007
Clinical presentation and response to therapy in patients with massive prolactin hypersecretion. Pituitary, 2007, Volume: 10, Issue:1 Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone	2007
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:5 Topics: Acromegaly; Adenoma, Acidophil; Adult; Cabergoline; Cell Proliferation; Cells, Cultured; Delayed-Action Preparations; Ergolines; Human Growth Hormone; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Microscopy, Electron; Octreotide; Pituitary Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Somatostatin; Thymidine	2007
Resolution of a hyperprolactinemia in a western lowland gorilla (Gorilla gorilla gorilla). Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians, 2006, Volume: 37, Issue:4 Topics: Animals; Antineoplastic Agents; Ape Diseases; Cabergoline; Ergolines; Female; Gorilla gorilla; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma; Reproduction; Treatment Outcome	2006
Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. Clinical endocrinology, 2007, Volume: 66, Issue:5 Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Body Height; Body Mass Index; Bromocriptine; Cabergoline; Combined Modality Therapy; Ergolines; Female; Growth Hormone; Growth Hormone-Secreting Pituitary Adenoma; Headache; Hormone Antagonists; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Male; Menstruation Disturbances; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Retrospective Studies; Somatostatin; Treatment Outcome	2007
Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. Journal of psychiatric practice, 2007, Volume: 13, Issue:2 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Clonazepam; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Follow-Up Studies; Humans; Patient Care Team; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Quinolones; Schizophrenia	2007
Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Pituitary, 2007, Volume: 10, Issue:3 Topics: Adolescent; Adult; Aged; Aminoquinolines; Cabergoline; Contraceptives, Oral, Hormonal; Dopamine Agonists; Ergolines; Female; Humans; Immunoglobulin G; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma	2007
Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline. Pituitary, 2008, Volume: 11, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Apoplexy; Pituitary Neoplasms; Prolactinoma; Tomography, X-Ray Computed	2008
Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clinical endocrinology, 2007, Volume: 67, Issue:3 Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Kaplan-Meier Estimate; Male; Middle Aged; Pituitary Neoplasms; Predictive Value of Tests; Prolactinoma; Prospective Studies; Regression Analysis; Remission Induction; ROC Curve; Secondary Prevention; Sex Distribution; Time Factors; Young Adult	2007
Dopaminergic treatment of nonfunctioning pituitary adenomas. Nature clinical practice. Endocrinology & metabolism, 2007, Volume: 3, Issue:8 Topics: Adenoma; Bromocriptine; Cabergoline; Dopamine Agents; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Prolactin	2007
Cabergoline treatment of pregnant women with macroprolactinomas. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2007, Volume: 99, Issue:1 Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Treatment Outcome	2007
Management of type 2 diabetes mellitus associated with pituitary gigantism. Pituitary, 2007, Volume: 10, Issue:4 Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diabetes Mellitus, Type 2; Ergolines; Gigantism; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pituitary Neoplasms; Radiotherapy	2007
Growth hormone producing prolactinoma in juvenile cystinosis: a simple coincidence? Pediatric nephrology (Berlin, Germany), 2008, Volume: 23, Issue:2 Topics: Administration, Oral; Administration, Topical; Body Height; Cabergoline; Child; Cysteamine; Cystinosis; Dopamine Agonists; Ergolines; Headache; Human Growth Hormone; Humans; Male; Ophthalmic Solutions; Pituitary Neoplasms; Prolactinoma; Radiation-Protective Agents; Treatment Outcome	2008
An important new adaption of a specific drug? Fertility and sterility, 2007, Volume: 88, Issue:2 Topics: Adenoma; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Neovascularization, Pathologic; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms; Polycystic Ovary Syndrome; Vascular Endothelial Growth Factor A	2007
A case of macroprolactinoma encasing an internal carotid artery aneurysm, presenting as pituitary apoplexy. Pituitary, 2008, Volume: 11, Issue:3 Topics: Angiography, Digital Subtraction; Antineoplastic Agents; Balloon Occlusion; Cabergoline; Carotid Artery, Internal; Dopamine Agonists; Ergolines; Headache; Humans; Intracranial Aneurysm; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Ophthalmoplegia; Pituitary Apoplexy; Pituitary Neoplasms; Prolactinoma; Treatment Outcome; Vision Disorders	2008
Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report. Minerva endocrinologica, 2007, Volume: 32, Issue:3 Topics: Adult; Cabergoline; Carcinoma; Combined Modality Therapy; Disease Progression; Dopamine Agonists; Drug Resistance; Ergolines; Fatal Outcome; Female; Humans; Octreotide; Pituitary Apoplexy; Pituitary Neoplasms; Prolactinoma; Radiosurgery; Subarachnoid Hemorrhage	2007
Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report. Surgical neurology, 2008, Volume: 69, Issue:1 Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2008
Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. The Journal of neuropsychiatry and clinical neurosciences, 2007,Fall, Volume: 19, Issue:4 Topics: Antidepressive Agents; Antineoplastic Agents; Cabergoline; Citalopram; Delusions; Depressive Disorder, Major; Ergolines; Female; Gambling; Humans; Middle Aged; Pituitary Neoplasms; Prolactinoma	2007
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. The pharmacogenomics journal, 2008, Volume: 8, Issue:5 Topics: Adenoma; Adult; Alleles; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Pituitary Neoplasms; Polymorphism, Genetic; Prolactin; Receptors, Dopamine D2; Retrospective Studies	2008
Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. European journal of endocrinology, 2008, Volume: 158, Issue:5 Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Ligands; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2; Receptors, Somatostatin; RNA, Messenger; Somatostatin; Tumor Cells, Cultured	2008
Nephrotic-range proteinuria in a patient with a giant prolactinoma. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 51, Issue:6 Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Prolactinoma; Proteinuria	2008
TSH-secreting adenoma improved with cabergoline. Annales d'endocrinologie, 2008, Volume: 69, Issue:3 Topics: Adult; Antineoplastic Agents; Bone and Bones; Cabergoline; Ergolines; Humans; Male; Pituitary Neoplasms; Thyrotropin; Thyroxine; Triiodothyronine	2008
In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors. Endocrine journal, 1995, Volume: 42, Issue:2 Topics: Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Cytoplasmic Granules; Dopamine Agonists; Endoplasmic Reticulum; Ergolines; Estradiol; Female; Microscopy, Electron; Organ Size; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred F344	1995
Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies. Endocrine journal, 1995, Volume: 42, Issue:3 Topics: Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred F344; Tumor Cells, Cultured	1995
Effectiveness of cabergoline in reducing follicle-stimulating hormone and prolactin hypersecretion from pituitary macroadenoma in an infertile woman. Fertility and sterility, 1994, Volume: 62, Issue:4 Topics: Adenoma; Adult; Amenorrhea; Cabergoline; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Humans; Infertility, Female; Pituitary Neoplasms; Pregnancy; Prolactin	1994
Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:6 Topics: Adenoma; Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Gonads; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Visual Fields	1996
Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:3 Topics: Adolescent; Adult; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Drug Resistance; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma	1997
Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clinical endocrinology, 1997, Volume: 46, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Infertility, Male; Male; Menstruation Disturbances; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma	1997
Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:8 Topics: Aminoquinolines; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma	1997
Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:8 Topics: Aminoquinolines; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma	1997
Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:9 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Carboplatin; Ergolines; Etoposide; Female; Gene Expression; Humans; Immunohistochemistry; Indium Radioisotopes; Magnetic Resonance Imaging; Middle Aged; Octreotide; Pituitary Neoplasms; Prolactinoma; Proto-Oncogene Mas; Proto-Oncogenes; Somatostatin; Treatment Failure	1997
Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone. Postgraduate medical journal, 1997, Volume: 73, Issue:862 Topics: Adenoma; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Follicle Stimulating Hormone; Humans; Male; Middle Aged; Pituitary Neoplasms	1997
Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. Journal of endocrinological investigation, 1997, Volume: 20, Issue:9 Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Kinetics; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactin	1997
Late development of resistance to bromocriptine in a patient with macroprolactinoma. Hormone research, 1998, Volume: 49, Issue:5 Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma	1998
Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. Journal of endocrinological investigation, 1999, Volume: 22, Issue:4 Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactin; Time Factors	1999
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. The Journal of clinical endocrinology and metabolism, 1999, Volume: 84, Issue:7 Topics: Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Drug Tolerance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Retrospective Studies; Sex Characteristics	1999
Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline. The Journal of clinical endocrinology and metabolism, 1999, Volume: 84, Issue:12 Topics: Antineoplastic Agents; Cabergoline; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma	1999
Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline. The Journal of clinical endocrinology and metabolism, 1999, Volume: 84, Issue:12 Topics: Antineoplastic Agents; Cabergoline; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma	1999
Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline. Hormone research, 1999, Volume: 52, Issue:1 Topics: Antineoplastic Agents; Cabergoline; Child; Ergolines; Exophthalmos; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma	1999
Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. Journal of endocrinological investigation, 1999, Volume: 22, Issue:11 Topics: Adenoma; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Nelson Syndrome; Pituitary Neoplasms; Remission Induction	1999
Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clinical endocrinology, 2000, Volume: 52, Issue:3 Topics: Adolescent; Adult; Aminoquinolines; Analysis of Variance; Biomarkers; Bone Density; Bone Remodeling; Bromocriptine; Cabergoline; Case-Control Studies; Collagen; Collagen Type I; Dopamine Agonists; Ergolines; Female; Femur Neck; Humans; Longitudinal Studies; Lumbar Vertebrae; Male; Middle Aged; Osteocalcin; Osteoporosis; Peptides; Pituitary Neoplasms; Prolactinoma; Regression Analysis	2000
Osteopenia in children and adolescents with hyperprolactinemia. Journal of pediatric endocrinology & metabolism : JPEM, 2000, Volume: 13, Issue:4 Topics: Adolescent; Antineoplastic Agents; Bone Density; Bone Diseases, Metabolic; Cabergoline; Child; Empty Sella Syndrome; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Prolactinoma; Puberty, Delayed	2000
Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. The Journal of clinical endocrinology and metabolism, 2000, Volume: 85, Issue:9 Topics: Adenoma, Acidophil; Adolescent; Antineoplastic Agents, Hormonal; Cabergoline; Delayed-Action Preparations; Dopamine Agonists; Ergolines; Female; Gigantism; Hormones; Humans; Magnetic Resonance Imaging; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; Stem Cells	2000
Images in thyroidology. Left exophthalmos of endocrine nonthyroid origin in a seven-year-old boy. Thyroid : official journal of the American Thyroid Association, 2000, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Cabergoline; Child; Ergolines; Exophthalmos; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma	2000
Cabergoline and quinagolide therapy for prolactinomas. Clinical endocrinology, 2000, Volume: 53, Issue:5 Topics: Aminoquinolines; Cabergoline; Cross-Over Studies; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactinoma; Research Design; Treatment Outcome	2000
Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas. Clinical endocrinology, 2000, Volume: 53, Issue:5 Topics: Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Hydrocortisone; Hypopituitarism; Insulin-Like Growth Factor I; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Recovery of Function; Treatment Outcome	2000
In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clinical endocrinology, 2001, Volume: 54, Issue:1 Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Prognosis; Thyrotropin	2001
Tumour shrinkage and chiasmal herniation after successful cabergoline treatment for a macroprolactinoma. Clinical endocrinology, 2001, Volume: 54, Issue:1 Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Hernia; Humans; Magnetic Resonance Imaging; Male; Optic Chiasm; Optic Nerve Diseases; Pituitary Neoplasms; Prolactinoma	2001
ACTH silent adenoma shrinking under cabergoline. European journal of endocrinology, 2001, Volume: 144, Issue:1 Topics: Adenoma; Adrenocorticotropic Hormone; Aged; Antineoplastic Agents; Autoradiography; Cabergoline; Ergolines; Humans; In Situ Hybridization; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2; RNA, Messenger	2001
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. Journal of endocrinological investigation, 2001, Volume: 24, Issue:2 Topics: Acromegaly; Adenoma; Adolescent; Amenorrhea; Bromocriptine; Cabergoline; Child; Ergolines; Female; Headache; Human Growth Hormone; Humans; Male; Neoplasm Recurrence, Local; Octreotide; Pituitary Neoplasms; Prolactinoma; Puberty, Delayed; Radiotherapy; Treatment Outcome; Vision Disorders; Visual Fields	2001
Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases. Journal of endocrinological investigation, 2001, Volume: 24, Issue:3 Topics: Adult; Cabergoline; Cerebrospinal Fluid Rhinorrhea; Endoscopy; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Tomography, X-Ray Computed	2001
In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clinical endocrinology, 2001, Volume: 54, Issue:4 Topics: Acromegaly; Adrenocorticotropic Hormone; Adult; Aminoquinolines; Analysis of Variance; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Growth Hormone; Humans; Immunohistochemistry; Indium Radioisotopes; Insulin-Like Growth Factor I; Iodine Radioisotopes; Luteinizing Hormone; Male; Octreotide; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine; Receptors, Somatostatin; Thyrotropin; Tumor Cells, Cultured	2001
Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia. Internal medicine (Tokyo, Japan), 2001, Volume: 40, Issue:9 Topics: Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2001
Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report. Pituitary, 2000, Volume: 3, Issue:4 Topics: Abdominal Pain; Acromegaly; Adenoma; Adult; Anti-Bacterial Agents; Bile Ducts, Intrahepatic; Bilirubin; Cabergoline; Chemical and Drug Induced Liver Injury; Cholangiopancreatography, Endoscopic Retrograde; Cholelithiasis; Cholesterol; Ergolines; Gram-Negative Bacterial Infections; Hepatectomy; Humans; Insulin-Like Growth Factor I; Liver; Liver Diseases; Male; Octreotide; Pituitary Neoplasms; Postoperative Complications; Sepsis; Surgical Wound Infection	2000
Giant prolactinomas presenting as skull base tumors. Surgical neurology, 2002, Volume: 57, Issue:2 Topics: Adult; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactin; Prolactinoma; Skull Base Neoplasms	2002
Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline. Journal of endocrinological investigation, 2002, Volume: 25, Issue:2 Topics: Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Dexamethasone; Ergolines; Glucocorticoids; Humans; Hydrocortisone; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Thyrotropin-Releasing Hormone; Treatment Outcome	2002
Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta endocrinologica, 1992, Volume: 126, Issue:6 Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Menstruation Disturbances; Middle Aged; Ovulation; Pituitary Neoplasms; Prolactinoma	1992
Osteocalcin levels in patients with microprolactinoma before and during medical treatment. Journal of endocrinological investigation, 1990, Volume: 13, Issue:5 Topics: Adolescent; Adult; Antineoplastic Agents; Bone Density; Cabergoline; Dihydroergotoxine; Dopamine Agents; Ergolines; Estradiol; Female; Humans; Hyperprolactinemia; Osteocalcin; Pituitary Neoplasms; Prolactin; Prolactinoma	1990
New perspectives in medical management of hyperprolactinemia. Endocrinologia experimentalis, 1990, Volume: 24, Issue:1-2 Topics: Adenoma; Bromocriptine; Cabergoline; Delayed-Action Preparations; Empty Sella Syndrome; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms	1990
Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration. Fertility and sterility, 1989, Volume: 52, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Pituitary Neoplasms; Prolactin; Prolactinoma; Time Factors; Tomography, X-Ray Computed	1989
Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. The Journal of clinical endocrinology and metabolism, 1989, Volume: 69, Issue:4 Topics: Adenoma; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin	1989
Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary. European journal of pharmacology, 1988, Jun-22, Volume: 151, Issue:1 Topics: Adenoma; Animals; Antineoplastic Agents; Body Weight; Bromocriptine; Cabergoline; DNA, Neoplasm; Ergolines; Estrogens; Female; Mitosis; Pituitary Neoplasms; Prolactin; Rats	1988